RESULT_COUNT: 231,PAGE_SIZE: 10000,CURRENT_PAGE: 1,TOTAL_PAGES: 1,API_CALL_CREDITS: 1
TICKER,FIGI_TICKER,FIGI,TITLE,PUBLICATION_DATE,URL,SUMMARY
GLPG,GLPG:UW,BBG000BJR4R8,The 1 Stock You've Been Overlooking for Your Roth IRA,2017-10-15 12:16:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/cr8uFZ4IVNw/the-1-stock-youve-been-overlooking-for-your-roth-ira-cm859880,Opening a Roth IRA account was one of your best moves in preparing for retirement I m assuming this applies to you If you don t have a Roth IRA get one This article will wait on you until you ve got one set up Seriously Roth IRAs are great retirement tools that many
GLPG,GLPG:UW,BBG000BJR4R8,"ETFs with exposure to Galapagos NV : October 5, 2017",2017-10-05 15:03:29 +0000,http://finance.yahoo.com/r/3c799fe2-894d-3e10-8a2c-2b5e745e247f/etfs-with-exposure-to-galapagos-nv-october-5-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Galapagos NV Here are 5 ETFs with the largest exposure to GLPG-US. Comparing the performance and risk of Galapagos NV with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more
<b>(Read more...)</b>"
GLPG,GLPG:UW,BBG000BJR4R8,Galapagos Pops After Eczema Drug Shows Promise Vs. Regeneron,2017-09-27 20:43:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/s91TmB0uU6c/galapagos-pops-after-eczema-drug-shows-promise-vs-regeneron-cm852063,Galapagos GLPG popped Wednesday after its eczema drug compared favorably with potential blockbuster Dupixent from Regeneron Pharmaceuticals REGN and Sanofi SNY in a Phase 1 trial ibd display video id 2322091 width 50 float left autostart true
GLPG,GLPG:UW,BBG000BJR4R8,Galapagos Pops After Eczema Drug Shows Promise Vs. Regeneron,2017-09-27 20:03:29 +0000,http://finance.yahoo.com/r/dbdb05bd-7e5a-365a-be08-845abbe52d2c/galapagos-pops-after-eczema-drug-shows-promise-vs-regeneron?src=A00220&yptr=yahoo&.tsrc=rss,Galapagos popped Wednesday after its eczema drug compared favorably with potential blockbuster Dupixent from Regeneron and Sanofi.
GLPG,GLPG:UW,BBG000BJR4R8,Galapagos and MorphoSys report first promising signs of clinical activity in a Phase 1 study with IL-17C antibody MOR106 in atopic dermatitis patients,2017-09-27 05:32:41 +0000,https://finance.yahoo.com/news/galapagos-morphosys-report-first-promising-053241727.html?.tsrc=rss,"Generally well-tolerated with no clinically relevant safety signals in Phase 1 study At the highest dose level, 5 out of 6 patients reached an improvement of at least 50% in atopic dermatitis symptoms ..."
GLPG,GLPG:UW,BBG000BJR4R8,Galapagos increases share capital through warrant exercises,2017-09-21 20:01:58 +0000,https://finance.yahoo.com/news/galapagos-increases-share-capital-warrant-200158006.html?.tsrc=rss,"Mechelen, Belgium; 21 September 2017, 22.00 CET; regulated information- Galapagos NV announces a share capital increase arising from warrant exercises.. Galapagos issued 28,100 new ordinary shares on 21 ..."
GLPG,GLPG:UW,BBG000BJR4R8,"ETFs with exposure to Galapagos NV : September 19, 2017",2017-09-19 21:37:32 +0000,http://finance.yahoo.com/r/d8bba453-4906-38b1-a043-da5a204de939/etfs-with-exposure-to-galapagos-nv-september-19-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Galapagos NV Here are 5 ETFs with the largest exposure to GLPG-US. Comparing the performance and risk of Galapagos NV with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more
<b>(Read more...)</b>"
GLPG,GLPG:UW,BBG000BJR4R8,"Galapagos NV :GLPG-US: Earnings Analysis: Q2, 2017 By the Numbers : September 18, 2017",2017-09-18 17:17:24 +0000,http://finance.yahoo.com/r/510bdd2f-d48b-3700-8d41-41affc148314/galapagos-nv-glpg-us-earnings-analysis-q2-2017-by-the-numbers-september-18-2017?yptr=yahoo&.tsrc=rss,"Categories:  Yahoo FinanceGet free summary analysis Galapagos NV reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Galapagos NV – GlaxoSmithKline plc Sponsored ADR, Johnson & Johnson, AbbVie, Inc., Sanofi Sponsored ADR, Merck & Co., Inc., Astrazeneca PLC Sponsored ADR, Fortress Biotech, Inc., Teva Pharmaceutical Industries ... Read more
<b>(Read more...)</b>"
GLPG,GLPG:UW,BBG000BJR4R8,2 Views on Vertex Pharmaceuticals Stock: Short Term vs. Long Term,2017-09-12 13:36:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wnSwdiJxJCY/2-views-on-vertex-pharmaceuticals-stock-short-term-vs-long-term-cm844171,There s a lot for investors to really like about Vertex Pharmaceuticals NASDAQ VRTX The company reached profitability earlier this year It has reported a string of positive clinical results for its cystic fibrosis drugs And oh yes the stock has more than doubled so far in
GLPG,GLPG:UW,BBG000BJR4R8,3 Reasons to Be Cautious on Vertex Pharmaceuticals Incorporated (VRTX) Stock,2017-08-29 18:15:27 +0000,https://finance.yahoo.com/news/3-reasons-cautious-vertex-pharmaceuticals-181527876.html?.tsrc=rss,"Biotech companies are a great source for finding huge gainers.  Founded in the late 1980s, Vertex Pharmaceuticals pioneered groundbreaking therapies for cystic fibrosis.  It was back in early 2012 that Vertex Pharmaceuticals received FDA approval for its drug, Kalydeco."
GLPG,GLPG:UW,BBG000BJR4R8,Vertex Pharmaceuticals Incorporated (VRTX) Stock Is Too Expensive,2017-08-21 21:39:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/u9e3qkHzC8Q/vertex-pharmaceuticals-incorporated-vrtx-stock-is-too-expensive-cm835009,InvestorPlace Stock Market News Stock Advice amp Trading Tips Vertex Pharmaceuticals Incorporated NASDAQ VRTX has turned in triple digit gains so far this year after news that the firm is on the verge of having several new cystic fibrosis treatments FDA approved That s a
GLPG,GLPG:UW,BBG000BJR4R8,Vertex Pharmaceuticals Incorporated (VRTX) Stock Is Too Expensive,2017-08-21 17:31:46 +0000,https://finance.yahoo.com/news/vertex-pharmaceuticals-incorporated-vrtx-stock-173146754.html?.tsrc=rss,"Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has turned in triple-digit gains so far this year after news that the firm is on the verge of having several new cystic fibrosis treatments FDA approved.  At $149.38 per share, VRTX stock is expensive, but the question is whether or not the stock is too expensive.  Have we already missed the boat or does the pharmaceutical company really have the growth potential that investors believe it does."
GLPG,GLPG:UW,BBG000BJR4R8,Why Vertex Pharmaceuticals Incorporated (VRTX) Stock Isn’t Worth the Risk,2017-08-14 14:25:16 +0000,https://finance.yahoo.com/news/why-vertex-pharmaceuticals-incorporated-vrtx-142516760.html?.tsrc=rss,"Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is enjoying a phenomenal 2017, up over 110% year-to-date.  Vertex Pharmaceuticals specializes in cystic fibrosis (CF) treatment.  Since its early days, Vertex has grown to become the world leader in CF treatment innovations, offering multiple patient options."
GLPG,GLPG:UW,BBG000BJR4R8,"Gainers & Losers Of Aug.10: SGMO, VTVT, EDIT, ACRS, CEMP...",2017-08-10 21:43:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dfs-8IbGlus/gainers--losers-of-aug10-sgmo-vtvt-edit-acrs-cemp-20170810-01601,"Gainers & Losers Of Aug.10: SGMO, VTVT, EDIT, ACRS, CEMP..."
GLPG,GLPG:UW,BBG000BJR4R8,"Pre-Market Most Active for Aug 10, 2017 :  M, QQQ, GLPG, KSS, CBI, TEVA, APRN, JCP, TVIX, XIV, AAPL, OPK",2017-08-10 12:53:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/18KHV2Fn1f4/pre-market-most-active-for-aug-10-2017-m-qqq-glpg-kss-cbi-teva-aprn-jcp-tvix-xiv-aapl-opk-cm829997,The NASDAQ 100 Pre Market Indicator is down 16 4 to 5 902 99 The total Pre Market volume is currently 5 780 422 shares traded The following are the most active stocks for the pre market session Macy s Inc M is 0 57 at 23 60 with 1 220 786 shares traded
GLPG,GLPG:UW,BBG000BJR4R8,"GLPG's FLORA Blooms, DVAX, ESPR Price Offering, SGMO Abuzz, HRTX On Track",2017-08-10 04:57:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PiVt_DrP4iE/glpgs-flora-blooms-dvax-espr-price-offering-sgmo-abuzz-hrtx-on-track-20170810-00170,"GLPG's FLORA Blooms, DVAX, ESPR Price Offering, SGMO Abuzz, HRTX On Track"
GLPG,GLPG:UW,BBG000BJR4R8,GLPG1690 halts disease progression in IPF patients in FLORA Phase 2a trial,2017-08-09 20:02:55 +0000,https://finance.yahoo.com/news/glpg1690-halts-disease-progression-ipf-200255968.html?.tsrc=rss,"Forced vital capacity in lungs stabilized over the 12- week treatment period, placebo arm showed expected decline Functional respiratory imaging confirms FVC data with statistical significance GLPG1690 ..."
GLPG,GLPG:UW,BBG000BJR4R8,"Should You Buy Vertex Pharmaceuticals Incorporated (VRTX) Stock? 3 Pros, 3 Cons",2017-08-03 18:02:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PX0MqOEn9Pk/should-you-buy-vertex-pharmaceuticals-incorporated-vrtx-stock-3-pros-3-cons-cm826756,InvestorPlace Stock Market News Stock Advice amp Trading Tips Vertex Pharmaceuticals Incorporated NASDAQ VRTX has shined bright within the biotech industry this year VRTX stock has more than doubled over the past 12 months That stands in stark contrast to the sector which
GLPG,GLPG:UW,BBG000BJR4R8,Is a Surprise Coming for Galapagos (GLPG) This Earnings Season?,2017-08-03 15:05:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TmZJ6SxloCk/is-a-surprise-coming-for-galapagos-glpg-this-earnings-season-cm826415,Investors are always looking for stocks that are poised to beat at earnings season and Galapagos NV GLPG may be one such company The firm has earnings coming up pretty soon and events are shaping up quite nicely for their report That is because Galapagos is seeing favorable
GLPG,GLPG:UW,BBG000BJR4R8,"Should You Buy Vertex Pharmaceuticals Incorporated (VRTX) Stock? 3 Pros, 3 Cons",2017-08-03 13:46:02 +0000,https://finance.yahoo.com/news/buy-vertex-pharmaceuticals-incorporated-vrtx-134602120.html?.tsrc=rss,"Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has shined bright within the biotech industry this year.  VRTX stock has more than doubled over the past 12 months.  Then the company added more fuel to the fire last month, with new drug data results coming in favorably."
GLPG,GLPG:UW,BBG000BJR4R8,Is a Surprise Coming for Galapagos (GLPG) This Earnings Season?,2017-08-03 12:57:12 +0000,https://finance.yahoo.com/news/surprise-coming-galapagos-glpg-earnings-125712804.html?.tsrc=rss,Galapagos (GLPG) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
GLPG,GLPG:UW,BBG000BJR4R8,GoPro (GPRO) to Report Q2 Earnings: A Beat in Store?,2017-08-01 15:59:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lezJ2u-tZaU/gopro-gpro-to-report-q2-earnings-a-beat-in-store-cm824998,GoPro Inc GPRO is slated to release second quarter 2017 results after the closing bell on Aug 3 The company has had a decent earnings history having beaten estimates thrice over the trailing four quarters for a modest average positive surprise of 4 2 Last quarter GoPro trumped
GLPG,GLPG:UW,BBG000BJR4R8,Quanta Services (PWR) Q2 Earnings: What's in the Cards?,2017-08-01 15:58:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Ug7aj69jQwc/quanta-services-pwr-q2-earnings-whats-in-the-cards-cm824974,Quanta Services Inc PWR is slated to report second quarter 2017 results before the opening bell on Aug 3 Quanta Services has had a dismal earnings surprise history with three misses and one in line earnings over the trailing four quarters for an average negative surprise of 17 3
GLPG,GLPG:UW,BBG000BJR4R8,Match Group (MTCH) to Report Q2 Earnings: What's in Store?,2017-07-31 16:01:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/XzqzCMx01Ms/match-group-mtch-to-report-q2-earnings-whats-in-store-cm824238,Match Group Inc MTCH is set to report second quarter 2017 earnings results on Aug 1 The company went public in Nov 2015 and in its first earnings announcement as a publicly traded company Match Group had missed earnings estimates by 5 3 The succeeding quarters proved to be better
GLPG,GLPG:UW,BBG000BJR4R8,Solid financials support R&D progress,2017-07-27 20:03:04 +0000,https://finance.yahoo.com/news/solid-financials-support-r-d-200304221.html?.tsrc=rss,"First half-year financial results: Revenues €73.0 M, an increase of €24.3 M compared to H1 2016 Operating loss €32.9 M, an increase of €8.6 M compared to H1 2016 Cash on 30 June 2017 of €1,263.2 M Raised ..."
GLPG,GLPG:UW,BBG000BJR4R8,Servier licenses GLPG1972 in osteoarthritis from Galapagos,2017-07-27 20:01:59 +0000,https://finance.yahoo.com/news/servier-licenses-glpg1972-osteoarthritis-galapagos-200159927.html?.tsrc=rss,"Mechelen, Belgium; Suresnes Cedex, France; 27 July 2017, 22.00 CET, regulated information- As a result of their research collaboration, Servier announces today that it has exercised its option to develop ..."
GLPG,GLPG:UW,BBG000BJR4R8,Vertex (VRTX) Q2 Earnings Top on Solid Cystic Fibrosis Sales,2017-07-27 15:05:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/81WQO4PMGoc/vertex-vrtx-q2-earnings-top-on-solid-cystic-fibrosis-sales-cm822391,Vertex Pharmaceuticals Incorporated VRTX reported second quarter 2017 earnings per share of 10 cents including the impact of stock based compensation expense which beat the Zacks Consensus Estimate of 6 cents Notably the company had posted a loss of 1 cent in the year ago quarter
GLPG,GLPG:UW,BBG000BJR4R8,Will Flowserve (FLS) Pull Off a Surprise in Q2 Earnings?,2017-07-25 16:09:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JV3LygRfv8s/will-flowserve-fls-pull-off-a-surprise-in-q2-earnings-cm821045,We expect Flowserve Corporation FLS to beat earnings when it reports second quarter 2017 results on Jul 27 after the closing bell The company posted a positive earnings surprise of 25 in the last reported quarter Overall Flowserve has an average positive surprise of 3 6 for the
GLPG,GLPG:UW,BBG000BJR4R8,Galapagos (GLPG) Looks Good: Stock Adds 6.2% in Session,2017-07-21 14:10:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PJwPujSz5eg/galapagos-glpg-looks-good-stock-adds-62-in-session-cm819285,Galapagos NV GLPG was a big mover last session as the company saw its shares rise over 6 on the day The move came on solid volume too with far more shares changing hands than in a normal session This breaks the recent trend of the company as the stock is now trading above the volatile
GLPG,GLPG:UW,BBG000BJR4R8,Galapagos (GLPG) Looks Good: Stock Adds 6.2% in Session,2017-07-21 12:50:12 +0000,https://finance.yahoo.com/news/galapagos-glpg-looks-good-stock-125012936.html?.tsrc=rss,"Galapagos (GLPG) was a big mover last session, as the company saw its shares rise over 6% on the day."
GLPG,GLPG:UW,BBG000BJR4R8,Vertex Pharmaceuticals Stock Is Soaring: Here's Why It's Still Not Too Late to Buy,2017-07-19 22:03:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8AWuR-WP-a4/vertex-pharmaceuticals-stock-is-soaring-heres-why-its-still-not-too-late-to-buy-cm818365,Just last week I wrote why you d be smart to buy Vertex Pharmaceuticals NASDAQ VRTX stock At that time Vertex was up around 70 for the year My argument then was that the stock was still undervalued even with a forward earnings multiple of 41 because of its growth
GLPG,GLPG:UW,BBG000BJR4R8,Vertex Hits Record High On Results Of Cystic Fibrosis Trial,2017-07-19 20:22:22 +0000,http://finance.yahoo.com/r/c3b41d7c-ab48-32af-a67d-f455cbbde526/vertex-hits-record-high-on-results-of-cystic-fibrosis-trial?src=A00220&yptr=yahoo&.tsrc=rss,"Vertex blasted to a record high Wednesday on trial data for regimens that should have cystic fibrosis patients &quot;breathing easy,&quot; an analyst says."
GLPG,GLPG:UW,BBG000BJR4R8,Why You're Smart to Buy Vertex Pharmaceuticals Stock,2017-07-15 17:44:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DV_ZdeHofnI/why-youre-smart-to-buy-vertex-pharmaceuticals-stock-cm816533,You might look at Vertex Pharmaceuticals NASDAQ VRTX stock and shake your head at its valuation After soaring more than 70 so far in 2017 shares of the biotech now trade at a whopping 180 times trailing 12 month earnings That s the kind of price tag that would cause
GLPG,GLPG:UW,BBG000BJR4R8,Why You&apos;re Smart to Buy Vertex Pharmaceuticals Stock,2017-07-15 16:03:00 +0000,http://finance.yahoo.com/r/5b1a79b6-9e38-35e1-a484-f324b89ab35a/why-youre-smart-to-buy-vertex-pharmaceuticals-stoc.aspx?yptr=yahoo&.tsrc=rss,Forget the sky-high valuation. Vertex Pharmaceuticals stock is a smart pick.
GLPG,GLPG:UW,BBG000BJR4R8,Galapagos Is More Attractive--But Don't Buy It Just Yet,2017-07-07 14:14:00 +0000,http://finance.yahoo.com/r/5fe16fb6-7dec-3e0a-8c07-ad08301fabe9/galapagos-is-more-attractivebut-dont-buy-it-just-yet-1499436888?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Galapagos N.V. ADR (GLPG) is up more than 18% in the past year, but over the past couple of months it has lagged some of its biotech peers, and that’s made the stock more appealing—but not enough to buy.  Remainder of the pipeline (ex-filgotinib) though unique and compelling is early and inherently risky, and we await early POC data to become more constructive."
GLPG,GLPG:UW,BBG000BJR4R8,Galapagos-Gilead Begin Phase II Study on Uveitis Candidate,2017-07-05 22:44:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NV7INQBrDGk/galapagos-gilead-begin-phase-ii-study-on-uveitis-candidate-cm812117,Galapagos NV GLPG has announced initiation of a new phase II study evaluating its lead pipeline candidate filgotinib for treatment of adult patients with non infectious uveitis The study will be led by its partner Gilead Sciences Inc GILD Note that Galapagos had signed a
GLPG,GLPG:UW,BBG000BJR4R8,Galapagos-Gilead Begin Phase II Study on Uveitis Candidate,2017-07-05 20:57:08 +0000,https://finance.yahoo.com/news/galapagos-gilead-begin-phase-ii-205708813.html?.tsrc=rss,"Galapagos NV (GLPG) has announced initiation of a new phase II study, evaluating its lead pipeline candidate filgotinib for treatment of adult patients with non-infectious uveitis."
GLPG,GLPG:UW,BBG000BJR4R8,New Phase 2 study with filgotinib in non-infectious uveitis,2017-07-05 05:31:51 +0000,https://finance.yahoo.com/news/phase-2-study-filgotinib-non-053151861.html?.tsrc=rss,"Mechelen, Belgium; 5 July 2017; 7.30 CET- Galapagos NV announces a new Phase 2 study investigating filgotinib in non-infectious uveitis, being led by filgotinib collaboration partner Gilead Sciences, Inc.. ..."
GLPG,GLPG:UW,BBG000BJR4R8,Is Vertex Pharmaceuticals Running Out of Steam or Taking a Breather?,2017-06-29 15:07:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/RA92Kf1b30k/is-vertex-pharmaceuticals-running-out-of-steam-or-taking-a-breather-cm809879,Vertex Pharmaceuticals NASDAQ VRTX has enjoyed a remarkable run so far in 2017 Just last week the biotech stock was up 81 year to date There has been a lot of good news for the developer of cystic fibrosis CF drugs However over the past few days Vertex stock has
GLPG,GLPG:UW,BBG000BJR4R8,Is Vertex Pharmaceuticals Running Out of Steam or Taking a Breather?,2017-06-29 13:23:00 +0000,http://finance.yahoo.com/r/0fb2a557-a738-3434-a97b-d1fb4a738c0d/is-vertex-pharmaceuticals-running-out-of-steam-or.aspx?yptr=yahoo&.tsrc=rss,"Vertex stock might be down a little from its recent highs, but don&apos;t think its tremendous run is over."
GLPG,GLPG:UW,BBG000BJR4R8,Galapagos increases share capital through warrant exercises,2017-06-20 20:01:48 +0000,https://finance.yahoo.com/news/galapagos-increases-share-capital-warrant-200148560.html?.tsrc=rss,"Mechelen, Belgium; 20 June 2017, 22.00 CET; regulated information- Galapagos NV announces a share capital increase arising from warrant exercises.. Galapagos issued 52,030 new ordinary shares on 20 June ..."
GLPG,GLPG:UW,BBG000BJR4R8,InPlay from Briefing.com,2017-06-20 07:57:13 +0000,https://finance.yahoo.com/news/inplay-briefing-com-125529772.html?.tsrc=rss,InPlay from Briefing.com
GLPG,GLPG:UW,BBG000BJR4R8,Galapagos' R&D Update 2017: rapidly advancing our product candidates,2017-06-20 05:32:29 +0000,https://finance.yahoo.com/news/galapagos-r-d-2017-rapidly-053229693.html?.tsrc=rss,"Filgotinib Darwin 3: improved activity, consistent safety parameters for filgotinib Ph2 studies initiated in 6 new indications Cystic fibrosis Three different triple combos in development Successful completion ..."
GLPG,GLPG:UW,BBG000BJR4R8,Monday's ETF with Unusual Volume: VSS,2017-06-05 19:00:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ieMLKUZiqzw/mondays-etf-with-unusual-volume-vss-cm798899,The Vanguard FTSE All World ex US Small Cap ETF VSS is seeing unusually high volume in afternoon trading Monday with over 651 000 shares traded versus three month average volume of about 130 000 Shares of VSS were off about 0 2 on the day Components of that ETF with the
GLPG,GLPG:UW,BBG000BJR4R8,"EcoR1 Capital, LLC Buys CytomX Therapeutics Inc, Cascadian Therapeutics Inc, Fate Therapeutics ...",2017-05-20 14:11:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/GrQiKk_BhVs/ecor1-capital-llc-buys-cytomx-therapeutics-inc-cascadian-therapeutics-inc-fate-therapeutics-cm792267,EcoR1 Capital LLC New Purchases CTMX CASC FATE OVAS JNCE RGLS VSAR VIVE DRNA CCXI Added Positions ACRS LIFE ATRA ASND IRWD BMY Reduced Positions FGEN XNCR SNDX GLPG KIN Sold Out ALXN ARDX FPRX EDIT CMRX EGLT DERM CYTK BPMX
GLPG,GLPG:UW,BBG000BJR4R8,Galapagos creates new warrant plan,2017-05-17 20:01:56 +0000,https://finance.yahoo.com/news/galapagos-creates-warrant-plan-200156792.html?.tsrc=rss,"Mechelen, Belgium; 17 May 2017, 22.00 CET; regulated information-- Galapagos NV announced today that its Board of Directors created 1,074,500 warrants under new warrant plans for the benefit of employees, ..."
GLPG,GLPG:UW,BBG000BJR4R8,Seven abstracts on filgotinib accepted by EULAR 2017,2017-05-15 20:02:02 +0000,https://finance.yahoo.com/news/seven-abstracts-filgotinib-accepted-eular-200202713.html?.tsrc=rss,"Mechelen, Belgium; 15 May 2017, 22.00 CET- Galapagos NV announces the acceptance of seven abstracts from several clinical and pre-clinical studies with the investigational agent filgotinib in rheumatoid ..."
GLPG,GLPG:UW,BBG000BJR4R8,3 Top Biotech Stocks For May,2017-05-11 15:05:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0UV5v70_W1I/3-top-biotech-stocks-for-may-cm787789,After a dreadful 2016 biotech stocks have rebounded nicely this year for a variety of reasons Most importantly though the specter of government mandated price caps on specialty medicines appears to have faded into the background at least for the time being So to take
GLPG,GLPG:UW,BBG000BJR4R8,3 Top Biotech Stocks For May,2017-05-11 13:17:00 +0000,http://finance.yahoo.com/r/9396a51d-aacf-301d-9ab6-e25289bb2423/3-top-biotech-stocks-for-may.aspx?yptr=yahoo&.tsrc=rss,These three biotechs could be stellar buys this month.
GLPG,GLPG:UW,BBG000BJR4R8,Galapagos presents three posters on filgotinib in Crohn's disease at DDW® 2017,2017-05-07 14:36:53 +0000,http://finance.yahoo.com/news/galapagos-presents-three-posters-filgotinib-143653519.html?.tsrc=rss,"Mechelen, Belgium; 7 May 2017, 16.35 CET- Galapagos NV announces the presentation of three posters from the Phase 2 FITZROY study of the investigational agent filgotinib in Crohn's Disease, at Digestive ..."
GLPG,GLPG:UW,BBG000BJR4R8,"Galapagos NV :GLPG-US: Earnings Analysis: Q1, 2017 By the Numbers : May 4, 2017",2017-05-04 14:50:21 +0000,http://finance.yahoo.com/r/e763dfd6-c79d-35a1-a936-cb50074ff3c1/galapagos-nv-glpg-us-earnings-analysis-q1-2017-by-the-numbers-may-4-2017?yptr=yahoo&.tsrc=rss,"Categories:  Yahoo FinanceGet free summary analysis Galapagos NV reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of Galapagos NV – GlaxoSmithKline plc Sponsored ADR, Johnson & Johnson, AbbVie, Inc., Merck & Co., Inc., Astrazeneca PLC Sponsored ADR and Abbott Laboratories (GSK-US, JNJ-US, ABBV-US, MRK-US, AZN-US and ... Read more
<b>(Read more...)</b>"
GLPG,GLPG:UW,BBG000BJR4R8,Gilead Sciences Inc.'s Revenue and Earnings Continue to Fall on Declining HCV Sales,2017-05-03 00:26:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ilBPHymKRLs/gilead-sciences-incs-revenue-and-earnings-continue-to-fall-on-declining-hcv-sales-cm783135,Just how bad will it be That was the question investors were asking in the days leading up to Gilead Sciences NASDAQ GILD announcement of its first quarter 2017 results Gilead provided an answer when it reported those results after the market closed on Tuesday But
GLPG,GLPG:UW,BBG000BJR4R8,InPlay from Briefing.com,2017-05-01 09:55:01 +0000,http://finance.yahoo.com/news/inplay-briefing-com-115750752.html?.tsrc=rss,InPlay from Briefing.com
GLPG,GLPG:UW,BBG000BJR4R8,"Monday Is D-Day For AEZS, Watch Out For MRUS, FDA Nod For RDUS & Takeda",2017-04-30 02:16:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/WZj7ayZCVd0/monday-is-dday-for-aezs-watch-out-for-mrus-fda-nod-for-rdus--takeda-20170430-00001,"Monday Is D-Day For AEZS, Watch Out For MRUS, FDA Nod For RDUS & Takeda"
GLPG,GLPG:UW,BBG000BJR4R8,Galapagos presents pre-clinical data with selective ADAMTS-5 inhibitor GLPG1972 for osteoarthritis at OARSI,2017-04-29 05:31:32 +0000,http://finance.yahoo.com/news/galapagos-presents-pre-clinical-data-053132105.html?.tsrc=rss,"Mechelen, Belgium; 29 April 2017, 7.30 CET- Galapagos NV announces presentation of pre-clinical pharmacology data with GLPG1972 at the Osteoarthritis Research Society International annual meeting today ..."
GLPG,GLPG:UW,BBG000BJR4R8,"ETFs with exposure to Galapagos NV : April 28, 2017",2017-04-28 19:53:25 +0000,http://finance.yahoo.com/r/38b3d65b-34bc-3511-9050-21bf343448f6/etfs-with-exposure-to-galapagos-nv-april-28-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Galapagos NV Here are 5 ETFs with the largest exposure to GLPG-US. Comparing the performance and risk of Galapagos NV with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more
<b>(Read more...)</b>"
GLPG,GLPG:UW,BBG000BJR4R8,Galapagos reports first quarter 2017 results,2017-04-27 20:01:22 +0000,http://finance.yahoo.com/news/galapagos-reports-first-quarter-2017-200122360.html?.tsrc=rss,Group revenues more than doubled to €39.9 million Operating loss reduced by 55% to €11.2 million Net loss of €13.6 million End of first quarter cash €958.6 million Start of new Proof-of-Concept studies ...
GLPG,GLPG:UW,BBG000BJR4R8,Galapagos announces new Phase 2 Proof-of-Concept study with filgotinib in cutaneous lupus erythematosus,2017-04-25 20:01:21 +0000,http://finance.yahoo.com/news/galapagos-announces-phase-2-proof-200121755.html?.tsrc=rss,"Mechelen, Belgium; 25 April 2017, 22.00 CET- Galapagos NV announces a new Phase 2 Proof-of-Concept study investigating filgotinib and another investigational agent in cutaneous lupus erythematosus. This ..."
GLPG,GLPG:UW,BBG000BJR4R8,Galapagos announces closing of public offering of American Depositary Shares for gross proceeds of €363.9 million,2017-04-21 20:03:32 +0000,http://finance.yahoo.com/news/galapagos-announces-closing-public-offering-200332833.html?.tsrc=rss,"Mechelen, Belgium; 21 April 2017, 22.01 CET; regulated information- Galapagos NV announced today the closing of its underwritten public offering of 4,312,500 American Depositary Shares, at a price of $90.00 ..."
GLPG,GLPG:UW,BBG000BJR4R8,"Pre-Market Most Active for Apr 18, 2017 :  BAC, MT, GNC, TOT, AAXJ, NFLX, CAH, BP, XIV, GLPG, ERIC, AUPH",2017-04-18 12:54:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/RodNT6Et5Yw/pre-market-most-active-for-apr-18-2017-bac-mt-gnc-tot-aaxj-nflx-cah-bp-xiv-glpg-eric-auph-cm775027,The NASDAQ 100 Pre Market Indicator is down 7 95 to 5 391 25 The total Pre Market volume is currently 5 161 990 shares traded The following are the most active stocks for the pre market session Bank of America Corporation BAC is 0 26 at 23 07 with 3 988 756
GLPG,GLPG:UW,BBG000BJR4R8,European Shares Retreat As Geopolitical Worries Mount,2017-04-18 06:04:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/86SnE22EqPg/european-shares-retreat-as-geopolitical-worries-mount-20170418-00206,European Shares Retreat As Geopolitical Worries Mount
GLPG,GLPG:UW,BBG000BJR4R8,Galapagos raises $338 million gross proceeds in a U.S. public offering,2017-04-18 02:11:06 +0000,http://finance.yahoo.com/news/galapagos-raises-338-million-gross-021106420.html?.tsrc=rss,"Mechelen, Belgium, 18 April 2017, 04.10 CET, regulated information- Galapagos NV announced today the pricing of its U.S. public offering totaling $338 million gross proceeds of 3,750,000 new ordinary shares ..."
GLPG,GLPG:UW,BBG000BJR4R8,Galapagos Raises $338 Mln Gross Proceeds In 3.75 Mln Shares US Public Offering,2017-04-17 23:49:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nAetvId8RuU/galapagos-raises-338-mln-gross-proceeds-in-375-mln-shares-us-public-offering-20170417-00962,Galapagos Raises $338 Mln Gross Proceeds In 3.75 Mln Shares US Public Offering
GLPG,GLPG:UW,BBG000BJR4R8,Galapagos announces launch of proposed public offering,2017-04-17 20:11:51 +0000,http://finance.yahoo.com/news/galapagos-announces-launch-proposed-public-201151994.html?.tsrc=rss,"Mechelen, Belgium, 17 April 2017, 22.10 CET, regulated information- Galapagos NV announced today that it intends to offer and sell, subject to market and other conditions, $275 million of its ordinary ..."
GLPG,GLPG:UW,BBG000BJR4R8,Illumina (ILMN) Launches VeriSeq NIPT Solution in Europe,2017-04-13 14:59:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-39W8yXYvqk/illumina-ilmn-launches-veriseq-nipt-solution-in-europe-cm773724,Global leader in the field of DNA sequencing and array based technologies Illumina Inc ILMN recently announced the launch of a solution pertaining to its noninvasive prenatal testing NIPT range in Europe The product VeriSeq NIPT solution is a CE IVD marked next generation
GLPG,GLPG:UW,BBG000BJR4R8,Galapagos increases share capital through warrant exercises,2017-04-06 20:01:55 +0000,http://finance.yahoo.com/news/galapagos-increases-share-capital-warrant-200155333.html?.tsrc=rss,"Mechelen, Belgium; 6 April 2017; regulated information- Galapagos NV announces a share capital increase arising from warrant exercises.. Galapagos issued 247,070 new ordinary shares on 6 April 2017, for ..."
GLPG,GLPG:UW,BBG000BJR4R8,Is Vertex Pharmaceuticals the Best Biotech Stock?,2017-04-05 20:55:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/85UbbGt7lQY/is-vertex-pharmaceuticals-the-best-biotech-stock-cm770384,Growing demand for its cystic fibrosis drugs suggests Vertex Pharmaceuticals NASDAQ VRTX 160 could be on the cusp of consistent profitability and if so then investors might be wise to add it to growth portfolios especially now that the company has announced positive late
GLPG,GLPG:UW,BBG000BJR4R8,Galapagos doses first psoriatic arthritis patient with filgotinib,2017-04-05 20:01:31 +0000,http://finance.yahoo.com/news/galapagos-doses-first-psoriatic-arthritis-200131757.html?.tsrc=rss,"First dosing triggers $10 million milestone payment from Gilead Mechelen, Belgium; 5 April 2017, regulated information- Galapagos NV announces dosing of the first patient with psoriatic arthritis in the ..."
GLPG,GLPG:UW,BBG000BJR4R8,"Amedisys (AMED) Poised on Strong Home Health, Risks Remain",2017-04-05 15:27:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/81cog7kUKig/amedisys-amed-poised-on-strong-home-health-risks-remain-cm770131,On Apr 04 we issued an updated research report on renowned home health and hospice services provider Amedisys Inc AMED The stock currently carries a Zacks Rank 3 Hold Over the last three months Amedisys consistently traded above the Zacks categorized Medical Outpatient and
GLPG,GLPG:UW,BBG000BJR4R8,Galapagos Initiates 3 Phase II Studies for Filgotinib,2017-04-04 23:24:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Umdv4bkan-Y/galapagos-initiates-3-phase-ii-studies-for-filgotinib-cm769899,Galapagos NV GLPG announced that it has initiated three new phase II Proof of Concept studies evaluating its pipeline candidate filgotinib in Sjogren s syndrome ankylosing spondylitis AS and psoriatic arthritis Galapagos and Gilead Sciences Inc GILD have partnered for the
GLPG,GLPG:UW,BBG000BJR4R8,Galapagos Initiates 3 Phase II Studies for Filgotinib,2017-04-04 20:55:08 +0000,http://finance.yahoo.com/news/galapagos-initiates-3-phase-ii-205508389.html?.tsrc=rss,"Galapagos NV (GLPG) announced that it has initiated three new phase II Proof-of-Concept studies evaluating its pipeline candidate filgotinib in Sjogren&apos;s syndrome, ankylosing spondylitis (AS), and psoriatic arthritis."
GLPG,GLPG:UW,BBG000BJR4R8,"QIAGEN Releases Favorable GeneReader Results, Expands in NGS",2017-04-04 17:26:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/MjDJ6XXnXlA/qiagen-releases-favorable-genereader-results-expands-in-ngs-cm769683,The Netherlands based QIAGEN N V QGEN a global provider of Sample to Insight solutions recently validated its GeneReader NGS System and published five new independent studies based on it at the Global Congress on Molecular Pathology in Berlin We believe the favorable outcome will fortify
GLPG,GLPG:UW,BBG000BJR4R8,3:16 am Galapagos NV announces the launch of 3 new Phase 2 Proof-of-Concept studies with filgotinib,2017-04-04 07:16:00 +0000,http://finance.yahoo.com/news/inplay-briefing-com-055139997.html#glpg,3:16 am Galapagos NV announces the launch of 3 new Phase 2 Proof-of-Concept studies with filgotinib
GLPG,GLPG:UW,BBG000BJR4R8,Galapagos announces three new Phase 2 Proof-of-Concept studies with filgotinib,2017-04-04 05:31:53 +0000,http://finance.yahoo.com/news/galapagos-announces-three-phase-2-053153768.html?.tsrc=rss,"Mechelen, Belgium; 4 April 2017; 7.30 CET- Galapagos NV announces three new Phase 2 Proof-of-Concept studies investigating filgotinib in Sjögren's syndrome, ankylosing spondylitis, and psoriatic arthritis. ..."
GLPG,GLPG:UW,BBG000BJR4R8,Galapagos announces three new Phase 2 Proof-of-Concept studies with filgotinib,2017-04-04 05:31:53 +0000,http://finance.yahoo.com/news/galapagos-announces-three-phase-2-053153768.html,"[GlobeNewswire] - Mechelen, Belgium; 4 April 2017; 7.30 CET- Galapagos NV announces three new Phase 2 Proof-of-Concept studies investigating filgotinib in Sjögren's syndrome, ankylosing spondylitis, and psoriatic arthritis. ..."
GLPG,GLPG:UW,BBG000BJR4R8,GALAPAGOS NV Financials,2017-03-29 17:04:05 +0000,http://finance.yahoo.com/q/is?s=glpg&annual,GALAPAGOS NV Financials
GLPG,GLPG:UW,BBG000BJR4R8,"The Zacks Analyst Blog Highlights: Milacron Holdings, Galapagos NV and Raymond James Financial",2017-03-24 16:03:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/QSM5S87jbqA/the-zacks-analyst-blog-highlights-milacron-holdings-galapagos-nv-and-raymond-james-financial-cm765265,For Immediate Release Chicago IL March 24 2017 Zacks com announces the list of stocks featured in the Analyst Blog Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets Stocks recently featured in the blog
GLPG,GLPG:UW,BBG000BJR4R8,"The Zacks Analyst Blog Highlights: Milacron Holdings, Galapagos NV and Raymond James Financial",2017-03-24 13:30:01 +0000,http://finance.yahoo.com/news/zacks-analyst-blog-highlights-milacron-133001664.html,"The Zacks Analyst Blog Highlights: Milacron Holdings, Galapagos NV and Raymond James Financial"
GLPG,GLPG:UW,BBG000BJR4R8,"The Zacks Analyst Blog Highlights: Milacron Holdings, Galapagos NV and Raymond James Financial",2017-03-24 13:30:01 +0000,http://finance.yahoo.com/news/zacks-analyst-blog-highlights-milacron-133001664.html?.tsrc=rss,"The Zacks Analyst Blog Highlights: Milacron Holdings, Galapagos NV and Raymond James Financial"
GLPG,GLPG:UW,BBG000BJR4R8,Publication of the annual report and invitation to the annual and extraordinary shareholders' meetings,2017-03-23 21:02:12 +0000,http://finance.yahoo.com/news/publication-annual-report-invitation-annual-210212440.html,"[GlobeNewswire] - Mechelen, Belgium; 23 March 2017- Today Galapagos NV published its Annual Report for the financial year 2016. The annual report for the financial year 2016, including a review of figures and performance, ..."
GLPG,GLPG:UW,BBG000BJR4R8,Publication of the annual report and invitation to the annual and extraordinary shareholders' meetings,2017-03-23 21:02:12 +0000,http://finance.yahoo.com/news/publication-annual-report-invitation-annual-210212440.html?.tsrc=rss,"Mechelen, Belgium; 23 March 2017- Today Galapagos NV published its Annual Report for the financial year 2016. The annual report for the financial year 2016, including a review of figures and performance, ..."
GLPG,GLPG:UW,BBG000BJR4R8,Galapagos Begins Cystis Fibrosis Treatment Study,2017-03-23 16:58:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/OlNLQs-A7sE/galapagos-begins-cystis-fibrosis-treatment-study-cm764781,Galapagos NV GLPG the Belgian clinical stage biotechnology company that collaborated with AbbVie Inc ABBV on a treatment for cystic fibrosis announced March 22 the phase 1 study to assess GLPG3067 s safety tolerability and pharmacokinetics began Galapagos NVGalapagos NV
GLPG,GLPG:UW,BBG000BJR4R8,Galapagos Begins Cystis Fibrosis Treatment Study,2017-03-22 21:22:29 +0000,http://finance.yahoo.com/news/galapagos-begins-cystis-fibrosis-treatment-212229923.html,Galapagos Begins Cystis Fibrosis Treatment Study
GLPG,GLPG:UW,BBG000BJR4R8,Galapagos Begins Cystis Fibrosis Treatment Study,2017-03-22 21:22:29 +0000,http://finance.yahoo.com/news/galapagos-begins-cystis-fibrosis-treatment-212229923.html?.tsrc=rss,"The study will test the treatment's safety, tolerability and pharmacokinetics"
GLPG,GLPG:UW,BBG000BJR4R8,"Health Care Sector Update for 03/22/2017: GLPG,ABBV,MBRX,VTL",2017-03-22 18:26:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/16cEH1G7IU0/health-care-sector-update-for-03222017-glpgabbvmbrxvtl-cm764289,Top Health Care StocksTop Health Care Stocks JNJ 0 59 JNJ 0 59 PFE 0 31 PFE 0 31 MRK 0 28 MRK 0 28 ABT 0 91 ABT 0 91 AMGN 0 06 AMGN 0 06 Health care stocks were slightly higher today with the NYSE Health Care Index adding about 0 1 in value in recent trade while shares of
GLPG,GLPG:UW,BBG000BJR4R8,Galapagos initiates Phase 1 study with novel CF potentiator GLPG3067,2017-03-22 06:31:57 +0000,http://finance.yahoo.com/news/galapagos-initiates-phase-1-study-063157156.html,"[GlobeNewswire] - Triggers a $7.5 M milestone payment from AbbVie Third potentiator in growing portfolio of cystic fibrosis drug candidates Mechelen, Belgium; 22 March 2017, 7.30 CET- Galapagos NV announces initiation of ..."
GLPG,GLPG:UW,BBG000BJR4R8,Galapagos initiates Phase 1 study with novel CF potentiator GLPG3067,2017-03-22 06:31:57 +0000,http://finance.yahoo.com/news/galapagos-initiates-phase-1-study-063157156.html?.tsrc=rss,"Triggers a $7.5 M milestone payment from AbbVie Third potentiator in growing portfolio of cystic fibrosis drug candidates Mechelen, Belgium; 22 March 2017, 7.30 CET- Galapagos NV announces initiation of ..."
GLPG,GLPG:UW,BBG000BJR4R8,Can The Uptrend Continue for Galapagos (GLPG)?,2017-03-16 14:08:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/aZufS55kgwI/can-the-uptrend-continue-for-galapagos-glpg-cm761540,Investors certainly have to be happy with Galapagos NV GLPG and its short term performance After all the stock has jumped by 14 9 in the past 4 weeks and it is also above its 20 Day Simple Moving Average as well This is certainly a good trend but investors are probably asking
GLPG,GLPG:UW,BBG000BJR4R8,Can The Uptrend Continue for Galapagos (GLPG)?,2017-03-16 12:22:12 +0000,http://finance.yahoo.com/news/uptrend-continue-galapagos-glpg-122212899.html,Can The Uptrend Continue for Galapagos (GLPG)?
GLPG,GLPG:UW,BBG000BJR4R8,Can The Uptrend Continue for Galapagos (GLPG)?,2017-03-16 12:22:12 +0000,http://finance.yahoo.com/news/uptrend-continue-galapagos-glpg-122212899.html?.tsrc=rss,Investors certainly have to be happy with Galapagos NV (GLPG) and its short term performance
GLPG,GLPG:UW,BBG000BJR4R8,Blog Coverage Galapagos Announced New Phase-II Studies Led by Filgotinib Collaboration Partner Gilead Sciences,2017-03-13 12:15:00 +0000,http://finance.yahoo.com/news/blog-coverage-galapagos-announced-phase-131500237.html,"[Accesswire] - Upcoming AWS Coverage on Emergent BioSolutions Post-Earnings Results LONDON, UK / ACCESSWIRE / March 13, 2017 / Active Wall St. blog coverage looks at the headline from Galapagos N.V. (NASDAQ: GLPG ) as ..."
GLPG,GLPG:UW,BBG000BJR4R8,Blog Coverage Galapagos Announced New Phase-II Studies Led by Filgotinib Collaboration Partner Gilead Sciences,2017-03-13 12:15:00 +0000,http://finance.yahoo.com/news/blog-coverage-galapagos-announced-phase-131500237.html?.tsrc=rss,"Upcoming AWS Coverage on Emergent BioSolutions Post-Earnings Results LONDON, UK / ACCESSWIRE / March 13, 2017 / Active Wall St. blog coverage looks at the headline from Galapagos N.V. (NASDAQ: GLPG ) as ..."
GLPG,GLPG:UW,BBG000BJR4R8,New Phase 2 studies with filgotinib in small bowel and fistulizing Crohn's disease,2017-03-10 06:31:12 +0000,http://finance.yahoo.com/news/phase-2-studies-filgotinib-small-063112203.html?.tsrc=rss,"Mechelen, Belgium; 10 March 2017- Galapagos NV announces two new Phase 2 studies investigating filgotinib in small bowel Crohn's disease as well as in fistulizing Crohn's disease. These studies are being ..."
GLPG,GLPG:UW,BBG000BJR4R8,New Phase 2 studies with filgotinib in small bowel and fistulizing Crohn's disease,2017-03-10 06:31:12 +0000,http://finance.yahoo.com/news/phase-2-studies-filgotinib-small-063112203.html,"[GlobeNewswire] - Mechelen, Belgium; 10 March 2017- Galapagos NV announces two new Phase 2 studies investigating filgotinib in small bowel Crohn's disease as well as in fistulizing Crohn's disease. These studies are being ..."
GLPG,GLPG:UW,BBG000BJR4R8,GLPG Crosses Above Average Analyst Target,2017-03-06 15:13:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/UVQv3KxYPo4/glpg-crosses-above-average-analyst-target-cm756514,In recent trading shares of Galapagos NV Symbol GLPG have crossed above the average analyst 12 month target price of 73 00 changing hands for 73 32 share When a stock reaches the target an analyst has set the analyst logically has two ways to react downgrade on valuation or re
GLPG,GLPG:UW,BBG000BJR4R8,Coverage initiated on Galapagos NV by Instinet,2017-03-02 13:43:14 +0000,http://finance.yahoo.com/q/ud?s=GLPG,Coverage initiated on Galapagos NV by Instinet
GLPG,GLPG:UW,BBG000BJR4R8,"Galapagos NV :GLPG-US: Earnings Analysis: Q4, 2016 By the Numbers : March 1, 2017",2017-03-01 14:42:52 +0000,http://www.capitalcube.com/blog/index.php/galapagos-nv-glpg-us-earnings-analysis-q4-2016-by-the-numbers-march-1-2017/,"Galapagos NV :GLPG-US: Earnings Analysis: Q4, 2016 By the Numbers : March 1, 2017"
GLPG,GLPG:UW,BBG000BJR4R8,"Galapagos NV :GLPG-US: Earnings Analysis: 2016 By the Numbers : February 28, 2017",2017-02-28 18:04:25 +0000,http://finance.yahoo.com/r/8118fa9d-c01f-3bd0-8e24-1d97494cb8e8/galapagos-nv-glpg-us-earnings-analysis-2016-by-the-numbers-february-28-2017?yptr=yahoo&.tsrc=rss,"Categories:   Yahoo Finance Get free summary analysis Galapagos NV reports financial results for the year ended December 31, 2016. We analyze the earnings along side the following peers of Galapagos NV – GlaxoSmithKline plc Sponsored ADR, Johnson & Johnson, AbbVie, Inc., Sanofi Sponsored ADR, Merck & Co., Inc., Astrazeneca PLC Sponsored ADR, Teva Pharmaceutical Industries Limited Sponsored ADR ... Read more    
<b>(Read more...)</b>"
GLPG,GLPG:UW,BBG000BJR4R8,"Galapagos NV :GLPG-US: Earnings Analysis: 2016 By the Numbers : February 28, 2017",2017-02-28 18:04:25 +0000,http://www.capitalcube.com/blog/index.php/galapagos-nv-glpg-us-earnings-analysis-2016-by-the-numbers-february-28-2017/,"Galapagos NV :GLPG-US: Earnings Analysis: 2016 By the Numbers : February 28, 2017"
GLPG,GLPG:UW,BBG000BJR4R8,Galapagos reports strong financial results and newsflow-rich pipeline,2017-02-23 21:01:46 +0000,http://finance.yahoo.com/news/galapagos-reports-strong-financial-results-210146772.html?.tsrc=rss,"Group revenues increased by €91.0 million to €151.6 million Operating loss reduced by €77.9 million to €11.5 million Net profit of €54.0 million, compared to a net loss of €118.4 million in 2015 Cash balance ..."
GLPG,GLPG:UW,BBG000BJR4R8,Galapagos reports strong financial results and newsflow-rich pipeline,2017-02-23 21:01:46 +0000,http://finance.yahoo.com/news/galapagos-reports-strong-financial-results-210146772.html,"[GlobeNewswire] - Group revenues increased by €91.0 million to €151.6 million Operating loss reduced by €77.9 million to €11.5 million Net profit of €54.0 million, compared to a net loss of €118.4 million in 2015 Cash balance ..."
GLPG,GLPG:UW,BBG000BJR4R8,Galapagos doses first healthy volunteer with CF combo GLPG2222 and GLPG2451,2017-02-23 21:01:13 +0000,http://finance.yahoo.com/news/galapagos-doses-first-healthy-volunteer-210113965.html,"[GlobeNewswire] - Mechelen, Belgium; 23 February 2017- Galapagos NV announces dosing of the first healthy volunteer with a combination of novel corrector GLPG2222 and novel potentiator GLPG2451 for cystic fibrosis in a ..."
GLPG,GLPG:UW,BBG000BJR4R8,Galapagos doses first healthy volunteer with CF combo GLPG2222 and GLPG2451,2017-02-23 21:01:13 +0000,http://finance.yahoo.com/news/galapagos-doses-first-healthy-volunteer-210113965.html?.tsrc=rss,"Mechelen, Belgium; 23 February 2017- Galapagos NV announces dosing of the first healthy volunteer with a combination of novel corrector GLPG2222 and novel potentiator GLPG2451 for cystic fibrosis in a ..."
GLPG,GLPG:UW,BBG000BJR4R8,BioTime (BTX) Shows Strength: Stock Adds 7.1% in Session,2017-02-22 15:12:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NKUEk1JqPVc/biotime-btx-shows-strength-stock-adds-71-in-session-cm751088,BioTime Inc BTX was a big mover last session as the company saw its shares rise above 7 on the day The move came on solid volume too with far more shares changing hands than in a normal session This breaks the trend for the company as the stock is now trading above the volatile price
GLPG,GLPG:UW,BBG000BJR4R8,BioTime (BTX) Shows Strength: Stock Adds 7.1% in Session,2017-02-22 13:28:01 +0000,http://finance.yahoo.com/news/biotime-btx-shows-strength-stock-132801192.html,BioTime (BTX) Shows Strength: Stock Adds 7.1% in Session
GLPG,GLPG:UW,BBG000BJR4R8,Galapagos NV Tests Cystic Fibrosis Treatment on First Patient,2017-02-03 19:32:04 +0000,http://finance.yahoo.com/news/galapagos-nv-tests-cystic-fibrosis-193204440.html,Galapagos NV Tests Cystic Fibrosis Treatment on First Patient
GLPG,GLPG:UW,BBG000BJR4R8,Galapagos NV Tests Cystic Fibrosis Treatment on First Patient,2017-02-03 19:32:04 +0000,http://finance.yahoo.com/news/galapagos-nv-tests-cystic-fibrosis-193204440.html?.tsrc=rss,The study's results will be published later this year
GLPG,GLPG:UW,BBG000BJR4R8,"Sanofi's Xyzal Now Available OTC, GLPG Kicks Off ALBATROSS, PRXL Opens Wallet",2017-02-02 01:55:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/yNRJvHSkwBg/sanofis-xyzal-now-available-otc-glpg-kicks-off-albatross-prxl-opens-wallet-20170202-00051,"Sanofi's Xyzal Now Available OTC, GLPG Kicks Off ALBATROSS, PRXL Opens Wallet"
GLPG,GLPG:UW,BBG000BJR4R8,Galapagos doses first patient with novel CF corrector GLPG2222,2017-02-01 21:02:05 +0000,http://finance.yahoo.com/news/galapagos-doses-first-patient-novel-210205847.html,"[GlobeNewswire] - IND opening triggers $10 million milestone payment from AbbVie. Mechelen, Belgium; 1 February 2017- Galapagos NV announces dosing of the first patient with cystic fibrosis Class III with novel CF corrector ..."
GLPG,GLPG:UW,BBG000BJR4R8,Galapagos doses first patient with novel CF corrector GLPG2222,2017-02-01 21:02:05 +0000,http://finance.yahoo.com/news/galapagos-doses-first-patient-novel-210205847.html?.tsrc=rss,"IND opening triggers $10 million milestone payment from AbbVie. Mechelen, Belgium; 1 February 2017- Galapagos NV announces dosing of the first patient with cystic fibrosis Class III with novel CF corrector ..."
GLPG,GLPG:UW,BBG000BJR4R8,Forget Incyte: Gilead Sciences Would Be Better Off Buying This Company,2017-01-26 14:13:16 +0000,http://www.fool.com/investing/2017/01/25/forget-incyte-gilead-sciences-would-be-better-off.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Forget Incyte: Gilead Sciences Would Be Better Off Buying This Company
GLPG,GLPG:UW,BBG000BJR4R8,Forget Incyte: Gilead Sciences Would Be Better Off Buying This Company,2017-01-26 14:13:16 +0000,http://finance.yahoo.com/r/c6f29787-ca68-3ff1-bfa4-54028a0f79be/forget-incyte-gilead-sciences-would-be-better-off.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2&yptr=yahoo&.tsrc=rss,Rumors have been swirling about the innovative biopharma's plans for its cash hoard. Here's why investors are focusing on the wrong target.
GLPG,GLPG:UW,BBG000BJR4R8,Forget Incyte: Gilead Sciences Would Be Better Off Buying This Company,2017-01-25 15:32:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/d7pH8_vl71c/forget-incyte-gilead-sciences-would-be-better-off-buying-this-company-cm737858,Image source Getty Images After successfully commercializing what became the world s most successful drug by annual sales numbers Gilead Sciences NASDAQ GILD has been forced to live with endless investor anxiety What will it do with all of that cash generated from its
GLPG,GLPG:UW,BBG000BJR4R8,Gilead Sciences Stock: What Could Go Wrong?,2017-01-24 20:41:08 +0000,http://www.fool.com/investing/2017/01/24/gilead-sciences-stock-what-could-go-wrong.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Gilead Sciences Stock: What Could Go Wrong?
GLPG,GLPG:UW,BBG000BJR4R8,Gilead Sciences Stock: What Could Go Wrong?,2017-01-24 20:41:08 +0000,http://finance.yahoo.com/r/bb56708d-04bf-3b42-abbc-5d0a67610381/gilead-sciences-stock-what-could-go-wrong.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2&yptr=yahoo&.tsrc=rss,Intense competition and clinical trial failures could be among the headwinds that weigh down the company's share price in 2017.
GLPG,GLPG:UW,BBG000BJR4R8,Galapagos creates new warrant plan,2017-01-20 21:04:08 +0000,http://finance.yahoo.com/news/galapagos-creates-warrant-plan-210408092.html?.tsrc=rss,"Mechelen, Belgium; 20 January 2017- Galapagos NV announced today that its Board of Directors created 150,000 warrants under a new warrant plan for the benefit of an employee of a subsidiary of the Company.. ..."
GLPG,GLPG:UW,BBG000BJR4R8,Galapagos creates new warrant plan,2017-01-20 21:04:08 +0000,http://finance.yahoo.com/news/galapagos-creates-warrant-plan-210408092.html,"[GlobeNewswire] - Mechelen, Belgium; 20 January 2017- Galapagos NV announced today that its Board of Directors created 150,000 warrants under a new warrant plan for the benefit of an employee of a subsidiary of the Company.. ..."
GLPG,GLPG:UW,BBG000BJR4R8,Dr. Walid Abi-Saab joins Galapagos as Chief Medical Officer,2017-01-17 21:05:38 +0000,http://finance.yahoo.com/news/dr-walid-abi-saab-joins-210538676.html?.tsrc=rss,"Mechelen, Belgium; 17 January 2017- Galapagos NV announces the appointment of Dr. Walid Abi-Saab to the role of Chief Medical Officer, beginning on 1 March 2017.. The Chief Medical Officer will be a member ..."
GLPG,GLPG:UW,BBG000BJR4R8,Dr. Walid Abi-Saab joins Galapagos as Chief Medical Officer,2017-01-17 21:05:38 +0000,http://finance.yahoo.com/news/dr-walid-abi-saab-joins-210538676.html,"[GlobeNewswire] - Mechelen, Belgium; 17 January 2017- Galapagos NV announces the appointment of Dr. Walid Abi-Saab to the role of Chief Medical Officer, beginning on 1 March 2017.. The Chief Medical Officer will be a member ..."
GLPG,GLPG:UW,BBG000BJR4R8,Why Galapagos (GLPG) Could Be Positioned for a Surge?,2016-12-29 15:01:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6Nk159NhNSk/why-galapagos-glpg-could-be-positioned-for-a-surge-cm727405,Galapagos NV GLPG is a Medial Biomedical and Genetics company that could be an interesting play for investors That is because not only does the stock have decent short term momentum but it is seeing solid activity on the earnings estimate revision front as well These positive
GLPG,GLPG:UW,BBG000BJR4R8,Why Galapagos (GLPG) Could Be Positioned for a Surge?,2016-12-29 13:30:01 +0000,http://finance.yahoo.com/news/why-galapagos-glpg-could-positioned-133001150.html,Why Galapagos (GLPG) Could Be Positioned for a Surge?
GLPG,GLPG:UW,BBG000BJR4R8,Galapagos NV Announces Results From Cystic Fibrosis Treatment Study,2016-12-27 19:48:20 +0000,http://finance.yahoo.com/news/galapagos-nv-announces-results-cystic-194820826.html,Galapagos NV Announces Results From Cystic Fibrosis Treatment Study
GLPG,GLPG:UW,BBG000BJR4R8,SAPHIRA 1 topline shows competitive clinical results in G551D patients,2016-12-20 21:52:04 +0000,http://www.publicnow.com/view/D69C6F9E57929737CCAF9A4E43A316CE5F58513D,"[at noodls] - Regulated information 20 December 2016, 22.00 CET First potentiator after Kalydeco®1to show comparable results in G551D patients GLPG1837 was generally well tolerated when dosed up to 500 mg twice daily ..."
GLPG,GLPG:UW,BBG000BJR4R8,3 Small Biotech Stocks That Big Biotechs Like,2016-12-19 20:09:24 +0000,http://www.fool.com/investing/2016/12/18/3-small-biotech-stocks-that-big-biotechs-like.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Small Biotech Stocks That Big Biotechs Like
GLPG,GLPG:UW,BBG000BJR4R8,Gilead Sciences Inc.'s Best Moves in 2016,2016-12-15 16:21:01 +0000,http://www.fool.com/investing/2016/12/15/gilead-sciences-incs-best-moves-in-2016.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Gilead Sciences Inc.'s Best Moves in 2016
GLPG,GLPG:UW,BBG000BJR4R8,Gilead Sciences Inc.'s Best Moves in 2016,2016-12-15 16:00:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/QGnav2_jL5E/gilead-sciences-incs-best-moves-in-2016-cm721921,Most investors would probably agree that Gilead Sciences Inc NASDAQ GILD had a pretty rotten year in 2016 Harvoni sales were down Sovaldi sales were down And of course Gilead s stock dropped more than 20 The big biotech certainly made some bad decisions during the year
GLPG,GLPG:UW,BBG000BJR4R8,The Lancet publishes FITZROY study results with filgotinib in Crohn's disease,2016-12-15 09:36:24 +0000,http://finance.yahoo.com/news/lancet-publishes-fitzroy-study-results-093624078.html,"[GlobeNewswire] - Mechelen, Belgium; 12 December 2016- Galapagos NV reports publication of the Phase 2 study with filgotinib in Crohn's disease in The Lancet.. ""Filgotinib, a selective JAK1 inhibitor, induces clinical ..."
GLPG,GLPG:UW,BBG000BJR4R8,Hedge Funds Are Betting On Galapagos NV (ADR) (GLPG),2016-12-14 06:29:51 +0000,http://www.insidermonkey.com/blog/hedge-funds-are-betting-on-galapagos-nv-adr-glpg-508463/,Hedge Funds Are Betting On Galapagos NV (ADR) (GLPG)
GLPG,GLPG:UW,BBG000BJR4R8,"FOLD Slowly Unfolding, EBS Continues Contract Spree, HZNP Plunges On Trial Data",2016-12-09 01:08:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/r0x3bVdhiw8/fold-slowly-unfolding-ebs-continues-contract-spree-hznp-plunges-on-trial-data-20161209-00013,"FOLD Slowly Unfolding, EBS Continues Contract Spree, HZNP Plunges On Trial Data"
GLPG,GLPG:UW,BBG000BJR4R8,Start Phase 2b/3 study with filgotinib in ulcerative colitis,2016-12-08 21:03:58 +0000,http://finance.yahoo.com/news/start-phase-2b-3-study-210358025.html,"[GlobeNewswire] - First patient dosed triggers a $10 million milestone payment. Mechelen, Belgium; 8 December 2016- Galapagos NV reports the first dosing of a patient in the SELECTION Phase 2 b/3 study with filgotinib in ..."
GLPG,GLPG:UW,BBG000BJR4R8,"Gilead Sciences, Inc.'s $10 Billion Mistake",2016-12-01 17:20:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qwCjkD6tJ4w/gilead-sciences-incs-10-billion-mistake-cm716429,Image source Getty Images Gilead Sciences Inc NASDAQ GILD is a cash generating machine bringing in 13 2 billion in free cash flow from operations so far this year which allowed the biotech to close two deals A licensing deal to gain access to
GLPG,GLPG:UW,BBG000BJR4R8,"Gilead Sciences, Inc.'s $10 Billion Mistake",2016-12-01 15:18:29 +0000,http://www.fool.com/investing/2016/12/01/gilead-sciences-incs-10-billion-mistake.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"Gilead Sciences, Inc.'s $10 Billion Mistake"
GLPG,GLPG:UW,BBG000BJR4R8,Testing of Treatment for Cystic Fibrosis Patients Begins,2016-11-29 21:19:37 +0000,http://finance.yahoo.com/news/testing-treatment-cystic-fibrosis-patients-211937554.html,Testing of Treatment for Cystic Fibrosis Patients Begins
GLPG,GLPG:UW,BBG000BJR4R8,Galapagos increases share capital through warrant exercises,2016-11-29 21:03:56 +0000,http://finance.yahoo.com/news/galapagos-increases-share-capital-warrant-210356817.html,"[GlobeNewswire] - Mechelen, Belgium, Nov. 29, 2016-- Mechelen, Belgium; 29 November 2016- Galapagos NV announces a share capital increase arising from warrant exercises.. Galapagos issued 86,250 new ordinary shares on 28 ..."
GLPG,GLPG:UW,BBG000BJR4R8,"Gilead Sciences, Inc. (GILD) Takes Lead Against AbbVie Inc (ABBV) On Crohn’s Disease Treatment",2016-11-29 17:17:03 +0000,http://www.insidermonkey.com/blog/gilead-sciences-inc-gild-takes-lead-against-abbvie-inc-abbv-on-crohns-disease-treatment-494729/,"Gilead Sciences, Inc. (GILD) Takes Lead Against AbbVie Inc (ABBV) On Crohn’s Disease Treatment"
GLPG,GLPG:UW,BBG000BJR4R8,Galapagos initiates Phase 1 study with cystic fibrosis drug GLPG2737,2016-11-28 21:04:01 +0000,http://finance.yahoo.com/news/galapagos-initiates-phase-1-study-210401663.html,"[GlobeNewswire] - Triggers $10 million milestone payment in collaboration with AbbVie. Mechelen, Belgium; 28 November 2016- Galapagos NV reports the initiation of a Phase 1 study in healthy volunteers with GLPG2737, a novel ..."
GLPG,GLPG:UW,BBG000BJR4R8,"Gilead Launches Phase 3 Crohn's Study (GILD, GLPG)",2016-11-28 17:32:00 +0000,http://www.investopedia.com/news/gilead-takes-lead-crohns-over-abbvie-gild-glpg/?partner=YahooSA,"Gilead Launches Phase 3 Crohn's Study (GILD, GLPG)"
GLPG,GLPG:UW,BBG000BJR4R8,Galapagos selected for Stoxx Europe 600 Index,2016-11-24 06:35:58 +0000,http://finance.yahoo.com/news/galapagos-selected-stoxx-europe-600-063558549.html,"[GlobeNewswire] - MECHELEN, Belgium, Nov. 24, 2016-- Galapagos NV announces that Stoxx has selected Galapagos NV for inclusion in the Stoxx Europe 600 Index, effective 19 December 2016.. ""After the inclusion of Galapagos ..."
GLPG,GLPG:UW,BBG000BJR4R8,Weighing In On Galapagos NV (ADR) (GLPG)’s Lead Studies,2016-11-23 18:49:06 +0000,http://www.insidermonkey.com/blog/weighing-in-on-galapagos-nv-adr-glpgs-lead-studies-490296/,Weighing In On Galapagos NV (ADR) (GLPG)’s Lead Studies
GLPG,GLPG:UW,BBG000BJR4R8,Galapagos (GLPG) Filgotinib in Phase III for Crohn's Disease,2016-11-23 15:07:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xQkrCIGLUuo/galapagos-glpg-filgotinib-in-phase-iii-for-crohns-disease-cm713167,Galapagos NV GLPG announced that it has dosed the first patient in a phase III study DIVERSITY on filgotinib for the treatment of Crohn s disease This triggered a milestone payment worth 50 million from Gilead Sciences Inc GILD The study will evaluate the safety and efficacy
GLPG,GLPG:UW,BBG000BJR4R8,Galapagos (GLPG) Filgotinib in Phase III for Crohn's Disease,2016-11-23 13:24:01 +0000,http://finance.yahoo.com/news/galapagos-glpg-filgotinib-phase-iii-132401182.html,Galapagos (GLPG) Filgotinib in Phase III for Crohn's Disease
GLPG,GLPG:UW,BBG000BJR4R8,Phase 3 study with filgotinib initiated in Crohn’s disease,2016-11-22 22:25:23 +0000,http://www.publicnow.com/view/B8D8A774ECCA3775F23100F2C700C01ED5FBAF77,"[at noodls] - Regulated information 22 November 2016, 22.00 CET Phase 3 study with filgotinib initiated in Crohn's disease First patient dosed triggers $50 million milestone payment Mechelen, Belgium; 22 November 2016 ..."
GLPG,GLPG:UW,BBG000BJR4R8,Phase 3 study with filgotinib initiated in Crohn's disease,2016-11-22 21:04:30 +0000,http://finance.yahoo.com/news/phase-3-study-filgotinib-initiated-210430347.html,"[GlobeNewswire] - MECHELEN, Belgium, Nov. 22, 2016-- Galapagos NV reports the first dosing of a patient in the DIVERSITY Phase 3 study with filgotinib in Crohn's disease. The start of the DIVERSITY study triggers a $50 ..."
GLPG,GLPG:UW,BBG000BJR4R8,"Galapagos NV :GLPG-US: Earnings Analysis: Q3, 2016 By the Numbers : November 8, 2016",2016-11-08 14:55:35 +0000,http://www.capitalcube.com/blog/index.php/galapagos-nv-glpg-us-earnings-analysis-q3-2016-by-the-numbers-november-8-2016/,"Galapagos NV :GLPG-US: Earnings Analysis: Q3, 2016 By the Numbers : November 8, 2016"
GLPG,GLPG:UW,BBG000BJR4R8,Why Celgene Corp Is a Better Buy Than Gilead Sciences,2016-11-03 21:08:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tsknLK6xbUg/why-celgene-corp-is-a-better-buy-than-gilead-sciences-cm703624,Image source Getty Images Over the past five years there have perhaps been no large cap biotech companies that have been as successful as Celgene Corp NASDAQ CELG and Gilead Sciences NASDAQ GILD New drug launches have resulted in sales and profit surging higher at
GLPG,GLPG:UW,BBG000BJR4R8,"After-Hours Earnings Report for October 28, 2016 :  GLPG, SPCB",2016-10-28 18:11:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/cVgA6W1aNj4/after-hours-earnings-report-for-october-28-2016-glpg-spcb-cm700463,The following companies are expected to report earnings after hours on 10 28 2016 Visit our Earnings Calendar for a full list of expected earnings releases Galapagos NV GLPG is reporting for the quarter ending September 30 2016 The biomedical
GLPG,GLPG:UW,BBG000BJR4R8,2 Reasons Celgene Corporation's Future Just Got Brighter,2016-10-28 17:33:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/AroJGtPJaMg/2-reasons-celgene-corporations-future-just-got-brighter-cm700415,Image source Getty Images The rearview mirror looks pretty good for Celgene Corporation NASDAQ CELG Blockbuster blood cancer drug Revlimid has powered the biotech to tremendous success Celgene s stock is up 340 over the past 10 years Unfortunately the present isn t
GLPG,GLPG:UW,BBG000BJR4R8,Galapagos Cystic Fibrosis Drug Trails Vertex's 'Mega-Franchise': RBC,2016-10-27 20:29:39 +0000,http://www.investors.com/news/technology/galapagos-cystic-fibrosis-drug-trails-vertexs-mega-franchise-rbc/,Galapagos Cystic Fibrosis Drug Trails Vertex's 'Mega-Franchise': RBC
GLPG,GLPG:UW,BBG000BJR4R8,Robust progress Q3 2016,2016-10-27 20:27:21 +0000,http://www.publicnow.com/view/3F82ABA4E473EA15AE903436FB0E75E84A80D798,"[at noodls] - Regulated information 27 October 2016, 22.00 CET Robust progress in Q3 2016 Financial results of the first nine months: Group revenues increased by €17.8 M to €65.0 M Operating loss reduced by €14.8 M ..."
GLPG,GLPG:UW,BBG000BJR4R8,Robust progress in Q3 2016,2016-10-27 20:09:18 +0000,http://finance.yahoo.com/news/robust-progress-q3-2016-200918329.html,"[GlobeNewswire] - Webcast presentation tomorrow 28 October at 14.00 CET/8 AM ET, www.glpg.com , +32 2 400 6926, code 2352766"
GLPG,GLPG:UW,BBG000BJR4R8,Galapagos to present progress in CF programs at NACFC 2016,2016-10-27 07:36:02 +0000,http://www.publicnow.com/view/169C073F624D5355401C408D0E512B1DE68D9672,"[at noodls] - Press release Nine posters and four oral presentations reflect clinical progress toward triple combination therapy Mechelen, Belgium; 27 October 2016, 7.30 CET - Galapagos NV (Euronext & NASDAQ: GLPG) ..."
GLPG,GLPG:UW,BBG000BJR4R8,What this Health Care analyst thinks will happen to the sector if Democrats take both the House and Senate,2016-10-25 21:03:12 +0000,http://finance.yahoo.com/tumblr/blog-what-this-health-care-analyst-thinks-will-happen-210316537.html,What this Health Care analyst thinks will happen to the sector if Democrats take both the House and Senate
GLPG,GLPG:UW,BBG000BJR4R8,Vertex Pharma Moves Next-Generation Cystic Fibrosis Drugs Into New Clinical Trials,2016-10-25 21:03:00 +0000,https://www.thestreet.com/story/13866789/1/vertex-pharma-moves-next-generation-cystic-fibrosis-drugs-into-new-clinical-trials.html?puc=yahoo&cm_ven=YAHOO,Vertex Pharma Moves Next-Generation Cystic Fibrosis Drugs Into New Clinical Trials
GLPG,GLPG:UW,BBG000BJR4R8,"Street Talk: CMG, NFX & more",2016-10-18 17:23:00 +0000,http://finance.yahoo.com/video/street-talk-cmg-nfx-more-172300373.html,"Street Talk: CMG, NFX & more"
GLPG,GLPG:UW,BBG000BJR4R8,Transparency notification – FMR LLC reaches 10% threshold,2016-10-12 20:20:04 +0000,http://www.publicnow.com/view/2917BEE6AE89280A0E39A5A17BE56E66C091FB14,"[at noodls] - Regulated information 12 October 2016, 22.00 CET Transparency notification - FMR LLC reaches 10% threshold Mechelen, Belgium; 12 October 2016 - Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency ..."
GLPG,GLPG:UW,BBG000BJR4R8,Transparency notification - FMR LLC reaches 10% threshold,2016-10-12 20:12:34 +0000,http://finance.yahoo.com/news/transparency-notification-fmr-llc-reaches-201234823.html,"[GlobeNewswire] - MECHELEN, Belgium -- Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from Fidelity Management & Research (FMR) LLC."
GLPG,GLPG:UW,BBG000BJR4R8,"Gilead Sciences, Inc. Is More Than an HCV Play (GILD)",2016-10-12 12:18:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/yr3DrbsCDOc/gilead-sciences-inc-is-more-than-an-hcv-play-gild-cm692199,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips A year ago almost to the day 160 Gilead Sciences Inc NASDAQ GILD was riding high GILD stock was basking in the glow of a 59 gain dished out during the twelve months before that on
GLPG,GLPG:UW,BBG000BJR4R8,"Vertex Orkambi's Label Expanded in U.S., Outlook Revised",2016-09-30 16:23:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/G3mWAg7IzEQ/vertex-orkambis-label-expanded-in-us-outlook-revised-cm687140,Vertex Pharmaceuticals Incorporated VRTX announced that its cystic fibrosis CF drug Orkambi was approved in the U S for the treatment of CF in patients aged 6 11 years who have two copies of the F508del mutation The company said that the drug will be available to the eligible
GLPG,GLPG:UW,BBG000BJR4R8,MorphoSys and Galapagos start first-in-patient dosing of IL-17C antibody MOR106 in atopic dermatitis,2016-09-29 08:00:11 +0000,http://www.publicnow.com/view/9203062324C7CB8E14F0440F6F78A15686DDAC72,"[at noodls] - Press Release 29 September 2016, 7.30 CET MorphoSys and Galapagos Start First-In-Patient Dosing of IL-17C Antibody MOR106 in Atopic Dermatitis Ongoing Phase 1 study in healthy volunteers now advanced to ..."
GLPG,GLPG:UW,BBG000BJR4R8,MorphoSys and Galapagos Start First-In-Patient Dosing of IL-17C Antibody MOR106 in Atopic Dermatitis,2016-09-29 05:40:28 +0000,http://finance.yahoo.com/news/morphosys-galapagos-start-first-patient-053612966.html,"[GlobeNewswire] - MECHELEN, Belgium and MARTINSRIED/MUNICH, Germany -- Galapagos NV (Euronext & NASDAQ: GLPG) and MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) announced today that the first patient ..."
GLPG,GLPG:UW,BBG000BJR4R8,"Gilead May Not Acquire Galapagos, For Now (GILD, GLPG)",2016-09-29 03:20:00 +0000,http://www.investopedia.com/news/gilead-may-not-acquire-galapagos-now-gild-glpg/?partner=YahooSA,"Gilead May Not Acquire Galapagos, For Now (GILD, GLPG)"
GLPG,GLPG:UW,BBG000BJR4R8,Successful completion of regulatory consultations to progress filgotinib to Phase 3 in inflammatory bowel disease,2016-09-27 21:09:08 +0000,http://www.publicnow.com/view/1D48D29E7AAE3A39C8E576641DDADF16FA937954,[at noodls] - Regulated information 27 September 2016 Global program to start in Q4'16 DIVERSITY Phase 3 study in Crohn's disease SELECTION Phase 2b/3 study in ulcerative colitis 100 mg and 200 mg once daily doses included ...
GLPG,GLPG:UW,BBG000BJR4R8,"ETF’s with exposure to Galapagos NV : September 27, 2016",2016-09-27 14:02:31 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-galapagos-nv-september-27-2016/,"ETF’s with exposure to Galapagos NV : September 27, 2016"
GLPG,GLPG:UW,BBG000BJR4R8,"Health Care Sector Update for 09/26/2016: GLPG,ARRY,PTIE",2016-09-26 18:01:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zJAwv4ui3Ck/health-care-sector-update-for-09262016-glpgarryptie-cm684712,Top Health Care StocksTop Health Care Stocks JNJ 0 93 JNJ 0 93 PFE 1 78 PFE 1 78 MRK 1 20 MRK 1 20 ABT 1 50 ABT 1 50 AMGN 0 91 AMGN 0 91 Health care stocks were sinking Monday afternoon with the NYSE Health Care Index falling about 1 1 while shares of health care companies in
GLPG,GLPG:UW,BBG000BJR4R8,Endoscopic improvements with filgotinib are consistent with clinical remission rates in patients with Crohn's disease,2016-09-26 07:19:06 +0000,http://www.publicnow.com/view/1984E6E287374D1F71B97CD5C651522C492E0EC2,"[at noodls] - Regulated information 26 September 2016, 02.00 CET Conference call 26 September at 14.00 CET/8 AM ET, +32 2 400 6926, code 8889838 Mechelen, Belgium; 26 September 2016 - Galapagos NV (Euronext & NASDAQ: ..."
GLPG,GLPG:UW,BBG000BJR4R8,Endoscopic improvements with filgotinib are consistent with clinical remission rates in patients with Crohn's disease,2016-09-26 00:20:40 +0000,http://finance.yahoo.com/news/endoscopic-improvements-filgotinib-consistent-clinical-002040204.html,"[GlobeNewswire] - MECHELEN, Belgium -- Galapagos NV (Euronext & NASDAQ: GLPG) reports that Dr Severine Vermeire, principal investigator of the FITZROY Phase 2 study with investigational agent filgotinib in Crohn's disease, ..."
GLPG,GLPG:UW,BBG000BJR4R8,Galapagos increases share capital through warrant exercises,2016-09-19 20:10:34 +0000,http://finance.yahoo.com/news/galapagos-increases-share-capital-warrant-201034850.html,"[GlobeNewswire] - MECHELEN, Belgium -- Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from warrant exercises."
GLPG,GLPG:UW,BBG000BJR4R8,Seeing the Same Old Patterns Ahead of Fed News,2016-09-19 14:55:00 +0000,http://realmoney.thestreet.com/articles/09/19/2016/seeing-same-old-patterns-ahead-fed-news?puc=yahoo&cm_ven=YAHOO,Seeing the Same Old Patterns Ahead of Fed News
GLPG,GLPG:UW,BBG000BJR4R8,"ETF’s with exposure to Galapagos NV : September 15, 2016",2016-09-15 14:03:00 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-galapagos-nv-september-15-2016/,"ETF’s with exposure to Galapagos NV : September 15, 2016"
GLPG,GLPG:UW,BBG000BJR4R8,Look Under The Hood: ADRD Has 12% Upside,2016-09-15 13:17:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/okqmg85TSPE/look-under-the-hood-adrd-has-12-upside-cm679814,Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For the
GLPG,GLPG:UW,BBG000BJR4R8,Orphan Drug Designation in European Union for GLPG1690 in idiopathic pulmonary fibrosis,2016-09-06 07:18:09 +0000,http://www.publicnow.com/view/7F3448C2EA50D4B12D173B4B5232DE4AB5D62797,"[at noodls] - Press release 6 September 2016, 07.30.00 CET Mechelen, Belgium; 6 September 2016: Galapagos (Euronext & NASDAQ: GLPG) announces today that the European Commission (EC) has granted GLPG1690 'orphan drug ..."
GLPG,GLPG:UW,BBG000BJR4R8,Galapagos: EC Grants GLPG1690 Orphan Drug Designation To Treat IPF Patients,2016-09-06 02:03:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vf5QTnYjtGk/galapagos-ec-grants-glpg1690-orphan-drug-designation-to-treat-ipf-patients-20160906-00051,Galapagos: EC Grants GLPG1690 Orphan Drug Designation To Treat IPF Patients
GLPG,GLPG:UW,BBG000BJR4R8,Gilead Sciences Inc.'s 5 Best Moves in 2016 So Far,2016-09-05 14:19:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/aGa-XFlATOo/gilead-sciences-incs-5-best-moves-in-2016-so-far-cm674639,Image source Getty Images Gilead Sciences NASDAQ GILD 160 can t seem to find a bottom Despite the stock trading at a dirt cheap forward price to earnings ratio of 6 8 cheap that is for a large cap biotech stock the company s shares have simply failed to catch a
GLPG,GLPG:UW,BBG000BJR4R8,2 Clinical-Stage Biotech Stocks to Buy,2016-08-31 12:04:50 +0000,http://www.fool.com/investing/2016/08/30/2-clinical-stage-biotech-stocks-to-buy.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,2 Clinical-Stage Biotech Stocks to Buy
GLPG,GLPG:UW,BBG000BJR4R8,2 Clinical-Stage Biotech Stocks to Buy,2016-08-31 11:50:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mAtXlmtdUa8/2-clinical-stage-biotech-stocks-to-buy-cm672087,"Image source  Kite Pharma.  Few drugs make it all the way from laboratory test tubes to pharmacy shelves, and that makes investing in clinical stage biotech stocks incredibly risky. However, risk tolerant investors"
GLPG,GLPG:UW,BBG000BJR4R8,"ETF’s with exposure to Galapagos NV : August 29, 2016",2016-08-29 15:28:06 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-galapagos-nv-august-29-2016/,"ETF’s with exposure to Galapagos NV : August 29, 2016"
GLPG,GLPG:UW,BBG000BJR4R8,Galapagos (GLPG) Advances RA Drug Filgotinib to Phase III,2016-08-23 15:50:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/EFhLAzMwU3g/galapagos-glpg-advances-ra-drug-filgotinib-to-phase-iii-cm668988,Galapagos NVGLPG announced the initiation of a phase III program (FINCH) on filgotinib for the treatment of rheumatoid arthritis (RA).  The program will comprise three studies that will evaluate the safety and efficacy of once daily
GLPG,GLPG:UW,BBG000BJR4R8,Galapagos (GLPG) Advances RA Drug Filgotinib to Phase III,2016-08-23 13:43:01 +0000,http://finance.yahoo.com/news/galapagos-glpg-advances-ra-drug-134301334.html,Galapagos (GLPG) Advances RA Drug Filgotinib to Phase III
GLPG,GLPG:UW,BBG000BJR4R8,FINCH filgotinib Phase 3 program initiated in rheumatoid arthritis,2016-08-22 20:18:03 +0000,http://www.publicnow.com/view/4725B34F36401C1C35EE979E0C3C17D3F909DBBD,"[at noodls] - Press Release 22 August 2016, 22.00 CET Three studies addressing a broad population of patients with active rheumatoid arthritis Filgotinib 100 mg and 200 mg, once daily dosing in males and females worldwide ..."
GLPG,GLPG:UW,BBG000BJR4R8,"ETF’s with exposure to Galapagos NV : August 11, 2016",2016-08-11 16:48:11 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-galapagos-nv-august-11-2016/,"ETF’s with exposure to Galapagos NV : August 11, 2016"
GLPG,GLPG:UW,BBG000BJR4R8,"Galapagos NV :GLPG-US: Earnings Analysis: Q2, 2016 By the Numbers : August 8, 2016",2016-08-08 17:01:33 +0000,http://www.capitalcube.com/blog/index.php/galapagos-nv-glpg-us-earnings-analysis-q2-2016-by-the-numbers-august-8-2016/,"Galapagos NV :GLPG-US: Earnings Analysis: Q2, 2016 By the Numbers : August 8, 2016"
GLPG,GLPG:UW,BBG000BJR4R8,"Galapagos NV :GLPG-BE: Earnings Analysis: Q2, 2016 By the Numbers : August 8, 2016",2016-08-08 05:36:43 +0000,http://www.capitalcube.com/blog/index.php/galapagos-nv-glpg-be-earnings-analysis-q2-2016-by-the-numbers-august-8-2016/,"Galapagos NV :GLPG-BE: Earnings Analysis: Q2, 2016 By the Numbers : August 8, 2016"
GLPG,GLPG:UW,BBG000BJR4R8,Market Has Not Yet Noticed Potential in Galapagos (GLPG); Have You?,2016-08-05 13:57:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DrsNK_9RG9k/market-has-not-yet-noticed-potential-in-galapagos-glpg-have-you-cm661089,"It can be very difficult to find companies that are both flying under the radar, and still might have potential for gains. Many times, stocks are off investors' radar screens for a reason, though there are some hidden gems"
GLPG,GLPG:UW,BBG000BJR4R8,Add Up The Pieces: ADRD Could Be Worth $22,2016-08-05 12:52:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/15HDdFYS_qU/add-up-the-pieces-adrd-could-be-worth-22-cm660901,"Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel , we have compared the trading price of each holding against the average analyst 12 month forward target price, and computed the weighted average"
GLPG,GLPG:UW,BBG000BJR4R8,Galapagos receives transparency notification from Federated,2016-08-01 07:51:13 +0000,http://www.publicnow.com/view/82D354A80F897D8480486C834962D927F3DD0F72,"[at noodls] - Regulated information 29 July 2016, 22.00 CET Mechelen, Belgium; 29 July 2016 - Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from Federated Equity Management Company of Pennsylvania. ..."
GLPG,GLPG:UW,BBG000BJR4R8,Focus on filgotinib and cystic fibrosis,2016-07-28 22:28:02 +0000,http://www.publicnow.com/view/6FCBEC3F39464F1E4ABD9F020454B8FD7305F512,"[at noodls] - Regulated information 28 July 2016, 22.00 CET First half-year financial results: Revenues €48.8 M, an increase of €11.9 M compared to H1 2015 Operating loss €24.3 M, an improvement of € 11.3 M compared ..."
GLPG,GLPG:UW,BBG000BJR4R8,Invitation to EGM and nomination of Mary Kerr for Galapagos' Board of Directors,2016-06-23 07:29:06 +0000,http://www.publicnow.com/view/1150789FDF271C60B390366841B002D9F8238483,"[at noodls] - Draft webcast 2015-04-20 Darwin 2 W12_draft for notice SENT.pptm Regulated information 23 June 2016, 7.30 CET Invitation to the Special and Extraordinary Shareholders' Meetings of 26 July 2016 - Nomination ..."
GLPG,GLPG:UW,BBG000BJR4R8,Invitation to the Special and Extraordinary Shareholders' Meetings of 26 July 2016 - Nomination of Mary Kerr for Galapagos' Board of Directors,2016-06-23 05:33:16 +0000,http://finance.yahoo.com/news/invitation-special-extraordinary-shareholders-meetings-053316257.html,"[GlobeNewswire] - MECHELEN, Belgium -- Galapagos NV (Euronext & NASDAQ: GLPG) has the honor to invite its Shareholders, Warrant Holders, Directors and Statutory Auditor to its Special and Extraordinary Shareholders' Meetings ..."
GLPG,GLPG:UW,BBG000BJR4R8,"ETF’s with exposure to Galapagos NV : June 20, 2016",2016-06-20 18:30:12 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-galapagos-nv-june-20-2016/,"ETF’s with exposure to Galapagos NV : June 20, 2016"
GLPG,GLPG:UW,BBG000BJR4R8,3 Reasons Gilead Sciences Is a Buy,2016-06-17 21:06:24 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Gf8w8YwldZI/3-reasons-gilead-sciences-is-a-buy-cm637241,"Image source  Flickr user stockmonkeys .  Drugmaking giant Gilead Sciences (NASDAQ  GILD) has fallen out of favor with investors because sales of its hepatitis C drugs are flat lining, but shunning Gilead"
GLPG,GLPG:UW,BBG000BJR4R8,"Galapagos NV :GLPG-NL: Earnings Analysis: Q1, 2016 By the Numbers : June 15, 2016",2016-06-15 09:54:09 +0000,http://www.capitalcube.com/blog/index.php/galapagos-nv-glpg-nl-earnings-analysis-q1-2016-by-the-numbers-june-15-2016/,"Galapagos NV :GLPG-NL: Earnings Analysis: Q1, 2016 By the Numbers : June 15, 2016"
GLPG,GLPG:UW,BBG000BJR4R8,Galapagos' R&D Update 2016,2016-06-15 07:09:06 +0000,http://www.publicnow.com/view/D4D07B2D7E75358DEC065B0FD6390CED4C11B188,"[at noodls] - Draft webcast 2015-04-20 Darwin 2 W12_draft for notice SENT.pptm Regulated information 15 June 2016, 7.30 CET Galapagos' R&D Update 2016 C1 corrector GLPG2222 for cystic fibrosis (CF) and GLPG1972 in osteoarthritis ..."
GLPG,GLPG:UW,BBG000BJR4R8,My Favorite Clinical-Stage Biotech Stocks to Buy,2016-06-11 20:14:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4pFu0MKsY1U/my-favorite-clinical-stage-biotech-stocks-to-buy-cm634169,"Image source  stockmonkeys.com , via Flickr .  Perhaps no industry faces tougher odds than biotechnology. Historically, 90% of drugs entering clinical trials have flopped, and failure rates in tough to treat indications, like"
GLPG,GLPG:UW,BBG000BJR4R8,My Favorite Clinical-Stage Biotech Stocks to Buy,2016-06-11 16:01:00 +0000,http://www.fool.com/investing/2016/06/11/my-favorite-clinical-stage-biotech-stocks-to-buy.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,My Favorite Clinical-Stage Biotech Stocks to Buy
GLPG,GLPG:UW,BBG000BJR4R8,Why Galapagos NV Shares Soared 30.5% in May,2016-06-09 22:14:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xTwZCU_SYo8/why-galapagos-nv-shares-soared-305-in-may-cm633235,"Image source  Flickr user Stockmonkeys.com.  What  After AbbVie Inc .(NYSE  ABBV) expanded a collaboration with the company to work on therapies for cystic fibrosis, shares in Galapagos NV (NASDAQ  GLPG)"
GLPG,GLPG:UW,BBG000BJR4R8,Why Galapagos NV Shares Soared 30.5% in May,2016-06-09 20:21:00 +0000,http://www.fool.com/investing/2016/06/09/why-galapagos-nv-shares-soared-305-in-may.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Why Galapagos NV Shares Soared 30.5% in May
GLPG,GLPG:UW,BBG000BJR4R8,Galapagos selected for AEX Index,2016-06-09 07:09:04 +0000,http://www.publicnow.com/view/201E3F99600440296E5A68FF08365C12A9C9A244,"[at noodls] - Press release Press release 9 June 2016, 7.30 CET Mechelen, Belgium; 9 June 2016 - Galapagos NV (Euronext & NASDAQ: GLPG) announces that Euronext has selected Galapagos NV for inclusion in the AEX®1Index ..."
GLPG,GLPG:UW,BBG000BJR4R8,Galapagos creates new warrant plan,2016-06-01 20:05:15 +0000,http://finance.yahoo.com/news/galapagos-creates-warrant-plan-200515183.html,"[GlobeNewswire] - Mechelen, Belgium -- Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors created 865,000 warrants under new warrant plans for the benefit of employees, directors and an independent ..."
GLPG,GLPG:UW,BBG000BJR4R8,Galapagos' RA Drug Filgotinib to Enter Phase III in 3Q16,2016-05-25 21:49:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ZENzYwwbsdw/galapagos-ra-drug-filgotinib-to-enter-phase-iii-in-3q16-cm626515,Galapagos NVGLPG announced that it has successfully concluded the end of phase II discussions with the FDA in the U.S. and the European Medicines Agency for the treatment of patients with rheumatoid arthritis (RA). The company also divulged details
GLPG,GLPG:UW,BBG000BJR4R8,FITZROY Phase 2 study with filgotinib in Crohn’s Disease presented as late breaker at DDW 2016,2016-05-25 20:16:07 +0000,http://www.publicnow.com/view/ED8AFD5F9B1123C251054F0E8D981055A4912D1D,"[at noodls] - Press release 25 May 2016, 22.00 CET FITZROY Phase 2 study with filgotinib in Crohn's Disease presented as late breaker at DDW 2016 Mechelen, Belgium; 25 May 2016: Galapagos (Euronext & NASDAQ: GLPG) announces ..."
GLPG,GLPG:UW,BBG000BJR4R8,FITZROY Phase 2 study with filgotinib in Crohn's Disease presented as late breaker at DDW 2016,2016-05-25 20:04:16 +0000,http://finance.yahoo.com/news/fitzroy-phase-2-study-filgotinib-200416214.html,"[GlobeNewswire] - MECHELEN, Belgium -- Galapagos (Euronext & NASDAQ: GLPG) announces the presentation of detailed results from the Phase 2 FITZROY study of filgotinib in Crohn's Disease, at Digestive Disease Week (DDW1) ..."
GLPG,GLPG:UW,BBG000BJR4R8,Galapagos' RA Drug Filgotinib to Enter Phase III in 3Q16,2016-05-25 19:51:07 +0000,http://finance.yahoo.com/news/galapagos-ra-drug-filgotinib-enter-195107591.html,Galapagos' RA Drug Filgotinib to Enter Phase III in 3Q16
GLPG,GLPG:UW,BBG000BJR4R8,Successful completion of End-of-Phase 2 FDA and EMA consultations in rheumatoid arthritis (RA),2016-05-24 20:26:02 +0000,http://www.publicnow.com/view/F47FFBA109A80B560D2702B4B89406FAA0EDEE92,"[at noodls] - Press release Regulated information 24 May 2016, 22.00 CET FINCH Phase 3 studies to start in Q3'16 Three registration studies addressing a broad population of RA patients 100 mg and 200 mg once daily dosing ..."
GLPG,GLPG:UW,BBG000BJR4R8,A Heavy Hitter Just Stepped Up to the Cystic Fibrosis Plate,2016-05-20 21:52:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8yb91em2bXY/a-heavy-hitter-just-stepped-up-to-the-cystic-fibrosis-plate-cm624400,"Image source  Galapagos NV.  Belgian biotech company Galapagos NV (NASDAQ  GLPG) may be one of the most important drugmakers you haven't heard of yet. It doesn't have any products to sell, but"
GLPG,GLPG:UW,BBG000BJR4R8,A Heavy Hitter Just Stepped Up to the Cystic Fibrosis Plate,2016-05-20 19:41:00 +0000,http://www.fool.com/investing/general/2016/05/20/a-heavy-hitter-just-stepped-up-to-the-cystic-fibro.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,A Heavy Hitter Just Stepped Up to the Cystic Fibrosis Plate
GLPG,GLPG:UW,BBG000BJR4R8,Listing of existing shares on Euronext Brussels & Amsterdam,2016-05-17 09:02:10 +0000,http://www.publicnow.com/view/8C763D8BED7D138B307579CBDE9F93221095843E,"[at noodls] - 13c721ad-e754-4e57-85db-4b42c2f8db8b.pdf Regulated information 17 May 2016, 7.00 CET Listing of existing shares on Euronext Brussels & Amsterdam Mechelen, Belgium; 17 May 2016: Galapagos (Euronext & NASDAQ: ..."
GLPG,GLPG:UW,BBG000BJR4R8,"Galapagos NV :GLPG-BE: Earnings Analysis: Q1, 2016 By the Numbers : May 13, 2016",2016-05-13 17:38:40 +0000,http://www.capitalcube.com/blog/index.php/galapagos-nv-glpg-be-earnings-analysis-q1-2016-by-the-numbers-may-13-2016/,"Galapagos NV :GLPG-BE: Earnings Analysis: Q1, 2016 By the Numbers : May 13, 2016"
GLPG,GLPG:UW,BBG000BJR4R8,"ETF’s with exposure to Galapagos NV : May 11, 2016",2016-05-11 23:42:45 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-galapagos-nv-may-11-2016/,"ETF’s with exposure to Galapagos NV : May 11, 2016"
GLPG,GLPG:UW,BBG000BJR4R8,"Galapagos NV :GLPG-US: Earnings Analysis: Q1, 2016 By the Numbers",2016-05-10 15:03:14 +0000,http://www.capitalcube.com/blog/index.php/galapagos-nv-glpg-us-earnings-analysis-q1-2016-by-the-numbers/,"Galapagos NV :GLPG-US: Earnings Analysis: Q1, 2016 By the Numbers"
GLPG,GLPG:UW,BBG000BJR4R8,Galapagos starts Phase 1 study with potentiator GLPG2451 for CF,2016-05-09 21:08:09 +0000,http://www.publicnow.com/view/B8E0BF7A2121C4046119E25C7DCBC084D61C4658,"[at noodls] - Regulated information 9 May 2016, 22.00 CET Galapagos earns $10 million milestone payment from AbbVie Mechelen, Belgium; 9 May 2016: Galapagos NV (Euronext & NASDAQ: GLPG) announces the start of a Phase ..."
GLPG,GLPG:UW,BBG000BJR4R8,Gilead Stock: Analyzing 5 Key Suppliers (GILD),2016-04-29 17:51:00 +0000,http://www.investopedia.com/articles/insights/042916/gilead-stock-analyzing-5-key-suppliers-gild.asp?partner=YahooSA,Gilead Stock: Analyzing 5 Key Suppliers (GILD)
GLPG,GLPG:UW,BBG000BJR4R8,"Gilead Sciences, Inc. Reports Disappointing Q1 Harvoni Sales",2016-04-29 17:10:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dM0TuqxncOQ/gilead-sciences-inc-reports-disappointing-q1-harvoni-sales-cm613901,Image Source  Gilead Sciences.  Gilead Sciences started off 2016 on a bad note. Shares of the big biotech fell more than 17% by February before bouncing back. Investors hoped
GLPG,GLPG:UW,BBG000BJR4R8,"Gilead Sciences, Inc. Reports Disappointing Q1 Harvoni Sales",2016-04-29 15:16:00 +0000,http://www.fool.com/investing/general/2016/04/29/gilead-sciences-inc-reports-disappointing-q1-harvo.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"Gilead Sciences, Inc. Reports Disappointing Q1 Harvoni Sales"
GLPG,GLPG:UW,BBG000BJR4R8,Galapagos and AbbVie expand their cystic fibrosis collaboration,2016-04-29 07:11:20 +0000,http://www.publicnow.com/view/9BA1C9FAA367D50099538F40F0F3B1E9931B6613,"[at noodls] - Draft webcast 2015-04-20 Darwin 2 W12_draft for notice SENT.pptm Regulated information 29 April 2016, 7.00 CET Strong commitment from Galapagos and AbbVie to accelerate development of a triple combination ..."
GLPG,GLPG:UW,BBG000BJR4R8,Galapagos kick-starts 2016 with Q1 cash position of €988 M,2016-04-28 20:59:07 +0000,http://www.publicnow.com/view/C6E6ACA85950568AAACCC250CC928387741F93BE,"[at noodls] - Regulated information 28 April 2016, 22.00 CET First quarter financial results: Group revenues €14.8 M Group net profit €35.9 M ... This is an abstract of the original noodl. To continue reading this document, ..."
GLPG,GLPG:UW,BBG000BJR4R8,Galapagos reports additional data with filgotinib from the Phase 2 FITZROY study,2016-04-22 07:20:28 +0000,http://www.publicnow.com/view/4AF1893A5D38F1A3930330FCDA4E6696A58B02DE,"[at noodls] - Press release Regulated information 21 April 2016, 22.00 CET Filgotinib: an investigational JAK-inhibitor shows efficacy in Crohn's disease Clinical responses continued from week 10 to week 20 Safety profile ..."
GLPG,GLPG:UW,BBG000BJR4R8,Galapagos initiates a Phase 2a study with GLPG1690 in idiopathic pulmonary fibrosis patients,2016-04-07 07:17:04 +0000,http://www.publicnow.com/view/48B81D53BC9D91EA89D97DD12A705A42A6E8F0A7,"[at noodls] - Press release Regulated information 6 April 2016, 22.00 CET Mechelen, Belgium; 6 April 2016 - Galapagos NV (Euronext & NASDAQ: GLPG) announced the start of its exploratory Phase 2a study with GLPG1690 ..."
GLPG,GLPG:UW,BBG000BJR4R8,Galapagos and MorphoSys initiate Phase 1 study in joint antibody program MOR106,2016-04-07 07:17:04 +0000,http://www.publicnow.com/view/509DA0919700E1396AAD86D2B9B44969C2233FC7,"[at noodls] - Press release Regulated information 7 April 2016, 7.30 CET Mechelen, Belgium and Martinsried/Munich, Germany; 7 April 2016 - Galapagos NV (Euronext & NASDAQ: GLPG) and MorphoSys AG (FSE: MOR; Prime Standard ..."
GLPG,GLPG:UW,BBG000BJR4R8,Galapagos increases share capital through warrant exercises,2016-04-05 15:22:20 +0000,http://www.publicnow.com/view/2B942FC81C325C51927BFC1718E645435FBBB872,"[at noodls] - Press release Regulated information 1 April 2016, 22.00 CET Mechelen, Belgium; 1 April 2016 - Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from warrant exercises. Galapagos ..."
GLPG,GLPG:UW,BBG000BJR4R8,Publication of the annual report and invitation to the Annual Shareholders’ Meetings,2016-03-27 17:04:30 +0000,http://www.publicnow.com/view/19600781BCE5F283D6A8F862D4482432387F6428,"[at noodls] - Press release Regulated information 25 March 2016, 22.00 CET Publication of the annual report and invitation to the Annual and Extraordinary Shareholders' Meetings Mechelen, Belgium; 25 March 2016 - Today ..."
GLPG,GLPG:UW,BBG000BJR4R8,Peek Under The Hood: ADRU Has 22% Upside,2016-02-16 15:53:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nbJg3beRt0I/peek-under-the-hood-adru-has-22-upside-cm580211,"Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel , we have compared the trading price of each holding against the average analyst 12 month forward target price, and computed the weighted average"
GLPG,GLPG:UW,BBG000BJR4R8,Is Gilead Sciences Finally Nearing a Bottom?,2016-02-07 14:18:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Q-HLO_3XD4M/is-gilead-sciences-finally-nearing-a-bottom-cm576007,"Image source  Gilead Sciences.  Gilead Sciences , the reigning HIV and hepatitis C drugmaker, has seen its shares drop by over 14% so far this year, according to data provided by"
GLPG,GLPG:UW,BBG000BJR4R8,Galapagos reports results with GLPG1205 in ulcerative colitis,2016-01-26 08:37:20 +0000,http://www.publicnow.com/view/AF521FC556E331E6F126E33891F216B1D5DB5D0E,"[at noodls] - Draft webcast 2015-04-20 Darwin 2 W12_draft for notice SENT.pptm Regulated information 26 January 2016, 7.30 CET Phase 2a study confirms good pharmacokinetics, safety and tolerability In... This is an ..."
GLPG,GLPG:UW,BBG000BJR4R8,"Transparency notification - Gilead Sciences, Inc. holds 14.75% of Galapagos shares",2016-01-25 08:17:05 +0000,http://www.noodls.com/view/CB5D26ADBB29B59044A7A7EBDCCD01BB4153627B,"[at noodls] - Draft webcast 2015-04-20 Darwin 2 W12_draft for notice SENT.pptm Regulated information 25 January 2016, 7.30 AM CET Mechelen, Belgium; 25 January 2016 - Transparency notification to Galapagos NV (Euronext ..."
GLPG,GLPG:UW,BBG000BJR4R8,Gilead Takes a Page Out of Celgene's Playbook,2016-01-23 18:21:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nrMjvnD6K7A/gilead-takes-a-page-out-of-celgenes-playbook-cm569456,"Gilead Sciences has a well deserved reputation as an excellent business purchaser. Its $11 billion Pharmasset acquisition in 2012 enabled Gilead to seize 90% market share in Hepatitis C, to the tune of more than"
GLPG,GLPG:UW,BBG000BJR4R8,Galapagos (GLPG) Gives Update on Cystic Fibrosis Program,2016-01-20 22:25:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/BZlef57b3WA/galapagos-glpg-gives-update-on-cystic-fibrosis-program-cm568197,"Galapagos NVGLPG , with partner AbbVie Inc. ABBV , announced its aim to develop a triple cystic fibrosis transmembrane conductance regulator (CFTR) combination therapy for the treatment of patients with cystic fibrosis (CF). In order to identify the triple"
GLPG,GLPG:UW,BBG000BJR4R8,Galapagos and Gilead complete closing of their global collaboration for filgotinib,2016-01-19 22:45:04 +0000,http://www.noodls.com/view/1FDF8E5184C35B337151A4FF7315D097987B4E89,"[at noodls] - Draft webcast 2015-04-20 Darwin 2 W12_draft for notice SENT.pptm Regulated information 19 January 2016, 22.40 CET Mechelen, Belgium and Foster City, CA, USA, 19 January 2016 - Galapagos NV (Euronext & ..."
GLPG,GLPG:UW,BBG000BJR4R8,Galapagos advances CF clinical development,2016-01-19 08:15:05 +0000,http://www.noodls.com/view/D1DC8512B1007870EA290132C1A2077A42F75374,"[at noodls] - Draft webcast 2015-04-20 Darwin 2 W12_draft for notice SENT.pptm Regulated information 19 January 2016, 7.30 CET Initiation of Phase 1 study with corrector GLPG2222, earning Galapagos a $10 million milestone ..."
GLPG,GLPG:UW,BBG000BJR4R8,Gilead Sciences' Galapagos Deal Advances It Toward a Multibillion-Dollar Market,2016-01-15 21:16:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ObUxnG2okMQ/gilead-sciences-galapagos-deal-advances-it-toward-a-multibillion-dollar-market-cm566452,"Image source  Gilead Sciences.  In December, the well heeled Gilead Sciences inked a collaboration deal with Galapagos on the JAK1 inhibitor filgotinib, and this week, the U.S. Federal Trade Commission granted"
GLPG,GLPG:UW,BBG000BJR4R8,Why Galapagos NV's Shares Bolted Higher in 2015,2016-01-14 15:14:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gTAKFjnmEzM/why-galapagos-nvs-shares-bolted-higher-in-2015-cm565662,"What   Over the course of 2015, the Belgian biotech Galapagos NV reported that its lead experimental candidate, filgotinib, was making major strides in its clinical development as an oral treatment for"
GLPG,GLPG:UW,BBG000BJR4R8,Gilead Seeks Approval for Tenofovir Alafenamide for HBV,2016-01-13 17:17:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/V4T4Jqjk4Kk/gilead-seeks-approval-for-tenofovir-alafenamide-for-hbv-cm565257,"Gilead Sciences, Inc.GILD announced that it has submitted a regulatory application to the FDA for once daily tenofovir alafenamide (TAF) 25 mg for the treatment of adults suffering from chronic hepatitis B virus (HBV) infection. The company also plans"
